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A short stereospecific synthesis of the carbocyclic 2-deoxynucleoside analogues 36 and 37 (Schemes 2 and
5) and 45 and 46 (Schemes 2 and 6) starting from optically active 8,9,10-trinorborn-5-en-2-one (1) is described.
As two functional groups capable to react with each other are present in the same molecule of the synthetic
carbanucleosides, the latter can form polymers similar to oligonucleotides.
Introduction. ± Since the first report on the specific inhibition of gene expression by
an oligonucleotide by Zamecnik and Stephenson in 1978 [1] [2], antisense oligonucleo-
tide methodology has become a promising tool in chemotherapy because of its
specificity and manifold applications [3 ± 5]. However, although some naturally
occurring phosphodiester oligonucleosides have been shown to inhibit the replication
of viruses in cell culture, the key to a wide application of oligonucleotide therapeutics
resides in the development of modified oligonucleotides, which should be more
resistent to degradation by naturally occurring nucleases. Actually, to achieve the
desired biological effects, synthetic oligonucleotides must meet the following require-
ments: i) their half-life in the biological medium must be long enough for the desired
action to take place inside the cell; ii) they must be able to penetrate the cell membrane
to reach their objectives, and iii) they must bind strongly enough to the targeted nucleic
acid sequence.
In principle, any one of the molecular components of an oligonucleotide (i.e., base,
sugar, or phosphodiester backbone) can be modified to obtain an antisense nucleotide
with specific affinity to a given segment of the targeted nucleic acid. Among these
different kinds of modifications, the replacement of a cycloalkane for the ribose moiety
is particularly promising since the synthetic nucleoside analogs ± so-called carbanu-
cleosides ± are resistent against acids and phosphorylase enzymes that cleave the
glycosidic linkage of normal nucleosides. Furthermore, the comparatively higher
lipophilicity of carbanucleosides is potentially advantageous for facilitating oral
administration and cell-wall penetration [6 ± 9]. On the other hand, since the isolation
of ()-(S)-aristeromycin from Streptomyces citricolor [10] and ()-neplanocin A from
Ampullariella regularis [11], the interest in this class of compounds has grown rapidly,
and other carbocyclic analogues of purine and pyrimidine nucleosides have been the
subject of a great deal of synthetic and biological study in the last decade.
1) Present address: Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
1
Published in Helvetica Chimica Acta, Vol. 87: 2245-2265, 2004
By analogy to the enzymatic synthesis of nucleic acids, a particularly straightfor-
ward approach to antisense oligonucleotides is based on the polymerization of
monomers containing two functional groups in the same molecule capable to react
together in the presence of a catalyst. In making the choice of the most appropriate
functional groups that meet this condition, it is obvious to consider first those which
lead to macromolecules of the types commonly synthesized in polymer chemistry, i.e.,
polycarboxylates and polyamides. On the other hand, the length of the chains joining
the carbanucleoside units must be appropriate to assure an intramolecular separation
between the monomer units in the polymer chain as similar as possible to that present
in nucleic acids. As a result of these considerations, the syntheses of three
carbadinucleotides of the type 4, 5, and 10 were designed, which should be accessible
from monomeric building blocks of the type represented by 2, 3, 7 (from 6), and 9
(from ()-8), and 9 (Scheme 1).
A straightforward synthesis of rac-2 and rac-3 (both as butyl esters bearing a
protecting group at the primary alcohol function) from rac-bicyclo[2.2.1]hept-5-en-2-
one (rac-1; short form: norbornenone) was carried out some years ago in our
laboratory, affording in a four-step sequence both epimers in an overall yield of 43%
each [12]. This approach proved to be more advantageous than an alternative synthesis
reported previously by Jenny et al., who obtained the methyl ester of rac-3 in 24% yield
in six reaction steps starting from racemic exo-norbornene-2-carbaldehyde [13] [14].
The present communication describes an improved procedure for the synthesis of
enantiomerically pure ()-norbornenone 1, as well as stereospecific syntheses of 2 and
7 therefrom. The latter is the appropriate counterpart to carbanucleoside 9 for the
construction of carbadinucleotide 10, as the smallest self-replicating unit suitable for
the synthesis of polycarbanucleotides, the length of which should enable hybridization
with natural DNA or RNA fragments. Carbanucleoside 9 should be readily accessible
from enantiomerically pure ()-8, which has been obtained by enzymatic resolution of
the racemate [15]. Ultimately, the syntheses of 2 and 7 described in the present work
take advantage of the fact that their common optically active cyclopentanone precursor
6 posses a C2 symmetry axis, giving rise to a sole enantiomer on reduction of the
carbonyl group.
Results and Discussion. ± Synthesis of Carbanucleosides 45 and 46. The Concept . . .
The (1R,2R)-isomer of 6 should be accessible from ()-norbornenone 1 by means of
the conventional methodology of opening the bicyclo[2.2.1]heptane skeleton by
BaeyerVilliger oxidation of the norbornanone derivative 12a (Scheme 2). Thus, the
key step of the reaction sequence represented by the framed formulae in Scheme 2 is
the introduction of the acetic acid chain at C(2) of the cyclopentane ring. This goal
should be achieved by cyclopropanation of the CC bond of 1 with a diazoacetate and
subsequent regioselective opening of the cyclopropane ring of 11 by cleaving the CC
bond vicinal to the carbonyl group. Depending on the diazocarboxylate used for the
cyclopropanation reaction, chemoselective transformation of the ester group of 13 (
14) prior to cleavage of the lactone ring enables to differentiate between both side
chains at C(1) and C(2). After cleavage of the lactone ring, the OH group of the
obtained hydroxycyclopentanediacetate is cis with respect to the acetic acid moiety
originating from the norbornenone skeleton (cf. 15 in Scheme 2) so that nucleophilic
2
substitution of the OH group by a nucleobase affords the corresponding carbanucleo-
side with the nucleobase cis to the modified acetic acid chain (cf. below, Scheme 6).
. . . and Its Realization. ()-Norbornenone 1 was obtained by asymmetrically
catalyzed DielsAlder cycloaddition of -bromoacrylaldehyde to cyclopentadiene as
reported by Corey and co-workers [16] [17] (Scheme 3). In contrast to Corey×s method,
however, the preparation diol 19 via epoxide 18 [18] proved to be more efficient and
reproducible than either the direct transformation of bromohydrine 17 [18] into 19 or
Scheme 1
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the transformation of 16 into the corresponding cyanohydrine via the oxime of the
former. Moreover, only negligible quantities of by-products were formed during the
synthesis of 18 and 19 (see Exper. Part). Finally, diol 19 was transformed into optically
pure (e.e. 97%) ()-norbornenone 1 by oxidation with sodium periodate following
the procedure described by Helmchen and co-workers [19].
The success of the next reaction step, cyclopropanation of the CC bond of 1, is
strongly dependent on the catalyst used (see Table). Actually, according to Hubert×s
Scheme 2 2)
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study on the mechanism of the reaction of -diazo esters with olefins [20], catalysts that
favor the formation of a metalolefin complex, which subsequently reacts with the
diazo compound, rather than the formation of a metalcarbene complex, reduce the
rate of dimerization of the carbenoid equivalent of the diazo compound, which is the
main undesired side reaction in this kind of cyclopropane synthesis. Both ()-
norbornenone 1 and ethane-1,2-diyl ketal 20 react in the presence of a palladium
catalysts yielding the corresponding cyclopropane derivative in high yield (Scheme 2).
As expected, carbene addition to the endocyclic CC-bond takes place from the
sterically less-hindered exo-side, although it lacks stereoselectivity in terms of the syn-
or anti-position of the carboxylate group with respect to the methano bridge of the
bicyclic substrate2). In the case of ethane-1,2-diyl ketal 21 the exo-configuration of the
cyclopropane moiety could be unequivocally demonstrated for both the syn- and anti-
isomer by NMR data.
No nuclearOverhauser effect (NOE) on the protons of the CH2(8) group of the tricycle of syn- and anti-21
was observed upon irradiation either of HC(2) or of HC(4). As both syn- and anti-21 can be transformed by
deprotection of the carbonyl group into the corresponding cyclopropanonorbornanone derivatives 11, the latter
Scheme 3
Table. Dependence of the Yield and syn/anti Stereoselectivity of the Cyclopropanation Reaction of 1 and 20 with
Ethyl Diazoacetate (EDA) on the Reaction Conditions
Catalyst Substrate Catal./substr.
ratio
EDA/substr.
ratioa)
Temp. [] Time [h]b) Yield [%]c) anti/syn
Ratio d)
[Rh2(OAc)4] 20 200 : 1 1 : 1 23 1.5 30 1.46
[Rh2(OAc)4] 20 100 : 1 1 : 1 45 1 50 1.80
[Cu(OTf)2] 20 100 : 1 1 : 1 23 1.5 38 2.33
[Cu(OTf)2] 20 100 : 1 1 : 1 45 1 68 2.41
[Pd(OAc)2] 20 100 : 1 1 : 1 23 1.5 83 1.38
[Pd(OAc)2] 20 100 : 1 1 : 1 45 1 90 1.16
[Pd(OAc)2] 20 50 : 1 1 : 1 45 1 87 1.23
[Pd(OAc)2] 20 100 : 1 1.2 : 1 45 1 100 1.16
[Pd(OAc)2] 1 100 : 1 1 : 1 45 1 94 1.05
[Pd(OAc)2] 1 100 : 1 1.2 : 1 45 1 100 1.05
a) A solution of EDA (0.5 mmol) in dry CH2Cl2 (12 ml) was added, under Ar, at constant flow rate during 2 h to
a stirred solution of the alkene (0.05 mmol) in CH2Cl2 (5 ml) containing the catalyst. b) Time after the addition
of EDA was completed. c) Yield of crude product before chromatographic separation. d) As determined by
1H-NMR spectroscopy.
2) The designation syn/anti refers to the position of the substituent at C(3) of the tricycle with respect to the
main-bridge atom C(8), i.e., less/more remote from C(8).
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must be also exo-configurated. Moreover, the assignment of the syn- and anti-configuration to the isomers of
ketal 21 was also possible by NOE difference spectroscopy, since the enhancement by 23.5% of the intensity of
the resonance signal at 1.77 ppm assigned to HC(3) of the tricycle observed on irradiation at HC(8) of anti-
21 requires a −cis×-arrangement of the involved H-atoms. On the other hand, the measured coupling constants
(3J(H,H) 2.6 Hz) between HC(3) and HC(2) or HC(4) are consistent with a trans-arrangement of the
coupling protons in anti-21 (a corresponding cis-arrangement usually results in 3J(H,H) 10 2 Hz) [21].
Unfortunately, however, reductive cleavage of the cyclopropane ring, which was
attempted by catalytic hydrogenation of the mixture of syn- and anti-stereoisomers of
11 (both as racemates), was not regioselective: the reaction product consisted of a
mixture of the desired 5-oxonorbornane-2-acetate rac-12a and its isomer rac-12b in a
ratio of roughly 1 :1 (Scheme 2). In view of this difficulty, we next attempted a
regioselective cleavage of the cyclopropane ring in consideration of the well-known
tendency of cyclopropylmethyl radicals to isomerize, yielding butene radicals [22]. As a
matter of fact, rearrangement of the cyclopropylmethyl radical 22, derived from 11,
may produce the two radicals 23 and 24, 23 being homoconjugated with the carbonyl
group of the norbornanone skeleton (Scheme 4). Although, a priori, the preparation of
radical 27 does not require the separation of syn- and anti-11 since the cyclopropane-
ring opening cancels the chirality of its C(2) atom, the following transformations were
carried out with the separated stereoisomers, thereby simplifying the characterization
of the obtained products. Thus, the ester groups of the ketals syn- and anti-21 were
reduced with LiAlH4 to yield the primary alcohols syn- and anti-25a, respectively
(Scheme 2). Following deprotection of the carbonyl group led to the corresponding
hydroxy ketones syn- and anti-26a, respectively, which were transformed subsequently
into the corresponding xanthates syn- and anti-26b. Radical-induced deoxygenation of
the latter (cf. [23]) led to a mixture of the 6- and 5-vinylnorbornanones 27a and 27b,
respectively, with a low preference (58 vs. 42%) for the undesired isomer 27a. This
result agrees with the calculated heats of formation of radicals centered at the C(5) and
C(6) atoms of norcamphor (bicyclo[2.2.1]heptane-2-one), which are practically
identical within the margin of error of the MNDO method [24]. On the contrary,
radical-induced deoxygenation of the xanthates syn- and anti-25b, derived from the
ketals syn- and anti-25a, respectively, proceeded with a marked preference for the 5-
vinyl isomer 28b, which was obtained in a 3 :1 ratio with respect to the (undesired) 6-
vinyl isomer 28a. Although not completely regioselective, the above reaction sequence
provides access (via 29 and 30) to hydroxy lactone 14 as a single isomer that could be
transformed in two steps into the desired carbanucleosides 45 and 46 (cf. below,
Scheme 6).
Stereospecific Synthesis of Carbanucleosides 36 and 37. Moreover, vinyl derivative
28b serves as an intermediate for the synthesis of carbanucleosides 36 and 37
Scheme 4
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(Scheme 5) as it can be easily transformed by ozonolysis and subsequent reduction of
the obtained aldehyde into 31, the methanol analogue of ethanol 29. Thus, after
deprotection of the carbonyl group, BaeyerVilliger oxidation of the norcampher
derivative 32 afforded hydroxy lactone 33, which was transformed by methanolysis into
the hydroxy cyclopentaneacetate 34a. Following the usual procedure, the primary-
alcohol group of 34a was selectively protected as (tert-butyl)diphenylsilyl ether 34b
and, after transformation of the secondary-alcohol group into the corresponding
mesylate ( 35), the latter was reacted either with adenine or with thymine to yield the
corresponding carbanucleosides 36 and 37, respectively. The same compounds (bearing
different protecting groups for the primary-alcohol and carboxylic acid functions) had
been obtained earlier, as racemates, by a different route [12].
Stereospecific Synthesis of Carbanucleosides 45 and 46. The unsatisfactory
regioselectivity observed in our attempts to cleave the cyclopropane ring of 11 and
25b by catalytic hydrogenation and radical-induced deoxygenation, respectively,
prompted us to postpone the ring opening to the next step of the originally intended
reaction sequence, namely the BaeyerVilliger oxidation of the carbonyl group of 11
(Scheme 6). However, when lactone syn-38was hydrogenated on Pd/C, only a low yield
(25%) of the undesired ring-opened isomer 39 was obtained, probably due to the
competitive reduction of the lactone moiety under these reaction conditions.
Scheme 5
7
According to a study of the regioselectivity of reductive cleavage of the cyclo-
propane ring by Musso and co-workers [25] [26], electron-withdrawing substituents
weaken the CC bond adjacent to the substituted C-atom, thus facilitating its
hydrogenolytic cleavage. Thus, it appeared advantageous to modify the proposed
Scheme 6 2)
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synthetic pathway including ketones syn- and anti-41 as intermediates (Scheme 6).
Both bicyclo[3.1.0]hexanones were readily accessible by oxidation of the correspond-
ing secondary alcohols syn- and anti-40, respectively. The latter were obtained on
methanolysis of the lactone moiety of syn- and anti-38, which took place under
transesterification of the carboxylate group at the cyclopropane ring. As expected,
hydrogenolytic cleavage of the cyclopropane ring of both syn- and anti-41 occurred at
the -bond adjacent to the carbonyl group yielding the C2-symmetric cyclopentanone
derivative 42 regioselectively. Racemic 42 (as the diethyl ester) has previously been
prepared in four steps starting with cyclopent-2-enone (cf. [27] [28]). Borohydride
reduction of 42 afforded the desired secondary alcohol 43 as a single isomer. It must be
pointed out that this outcome of the synthesis of 43 confirms unequivocally the relative
trans-configuration at the C(1) and C(2) atoms, since a cis-isomer resulting from an
endo-cyclopropanonorbornanone derivative would afford two diastereomeric cyclo-
pentanol derivatives with opposite configuration at the pseudoasymmetric C(4) atom.
A manifest advantage of the above synthetic strategy is the C2 symmetry of
intermediate 42, which prevents the formation of stereoisomers on replacement of the
carbonyl group by a tetragonal C-atom. Moreover, the same strategy offers a simple
possibility to differentiate between the two acetic acid chains at C(1) and C(2), since
lactonization of 43 yields a single product, 13a, which, on transesterification with
benzylic alcohol and subsequent hydrogenolysis of the benzyl ester group, affords the
monocarboxylic acid 13c (Scheme 6). Diborane reduction of the carboxylic acid group
of 13c took place chemoselectively, thus yielding the primary alcohol 14, which was
finally transformed into 15a by methanolysis of the lactone ring. After protecting the
primary alcohol function of 15a, the resulting silyl ether 15b was transformed with
methanesulfonyl chloride to the mesylate 44, which was subjected to nucleophilic
substitution with either adenine or thymine to yield the carbanucleosides 45 and 46,
respectively.
Conclusions. ± In summary, the present work describes a straightforward stereo-
specific synthesis of the four carbanucleosides 36, 37, 45, and 46 from optical active
norbornen-2-one 1 as a readily accessible starting material. As in each carbanucleoside
the two functional groups (OH and COOH) can be deprotected selectively, the
monomeric building blocks are suitable for the direct synthesis of polyester analogs of
nucleotides or, alternatively, for the stepwise synthesis of heteromeric polynucleotide
analogs.
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Experimental Part
General. Solvents were generally dried and distilled prior to use. All air- and H2O-sensitive reactions were
carried out under Ar. The 3-chloroperbenzoic acid (MCPBA), N,N-dimethylpyridin-4-amine (DMAP),
tetrahydrofuran (THF), pyridinium chlorochromate (PCC), and other reagents were purchased from Fluka
Chemie AG, CH-9471 Buchs. TLC (reaction monitoring): E. Merck silica-gel 60 F254 (0.2 mm) precoated
aluminium plates (20 20 cm); detection by UV light (254 and 366 nm) or 1% aq. 2,4-dinitrophenylhydrazine
soln. (prepared by dissolving 0.4 g of 2,4-dinitrophenylhydrazine in 100 ml of 2HCl), or alkaline KMnO4 soln.
(prepared by dissolving 3 g of KMnO4 and 20 g of K2CO3 in 300 ml of H2O, followed by addition of 3 ml of 5%
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aq. NaOH soln.). Column chromatography (CC) and flash column chromatography (FC): silica gel 60 (0.063 ±
0.200 mm, 700 ± 230 mesh) and silica gel 60 (0.040 ± 0.063 mm, 230 ± 400 mesh), respectively, from E. Merck AG.
M.p.s: Kofler hot-stage apparatus (Thermovar, C. Reichert AG, Vienna) equipped with a digital
thermometer; uncorrected. Optical rotations []D: Perkin-Elmer-241-MV polarimeter; in deg ml g1 dm1), c
in g/100 ml. UV/VIS Spectra: Hewlett-Packard-8452A diode array spectrophotometer; max () in nm. IR
Spectra:Mattison 5000 FT-IR ;  in cm1. NMR Spectra: Varian-Gemini-200 (200.00 (1H) and 50.30 MHz (13C)),
Bruker-AM-360 (360.14 (1H) and 90.57 MHz (13C)), and Bruker-Advance-DRX-500 (500.13 (1H) and
125.76 MHz (13C)) spectrometer; CDCl3 solns., when not given otherwise; chemical shifts  in ppm rel. to
Me4Si as internal standard, J values in Hz; assignments based on homonuclear COSY; 1H{1H}NOE difference
correlations attached proton test (APT) and/or chemical shifts; NOE: indication of  of enhanced signal (%
enhancement, irradiated ). MS: Vacuum Generator Micromass 7070 E ; EI (electron ionization) at 70 eV; in
m/z (rel. %). High-resolution (HR) MS: Bruker 4.7T-BioApexII (FT-MS). Combustion analyses were carried
out by Ilse Beetz, Microanalytical Laboratory, Kronach, Germany.
()-(1R,4R)-Bicyclo[2.2.1]hept-5-en-2-one (1). Oxidation of 19 with sodium periodate according to [19]
gave 1. Colorless oil. []26D 1107.2 (c 0.41, CHCl3) ([29]: []23D 1033 (c 1.01, CHCl3)).
Ethyl (1R,2R,3R,4R,5R)- and (1R,2R,3S,4R,5R)-6-Oxotricyclo[3.2.1.02.4]octane-3-carboxylate (syn- and
anti-11). A mixture of 1 (9.73 g, 90 mmol) (cf. [19]) and [Pd(OAc)2] (202 mg, 0.9 mmol) in dry freshly distilled
CH2Cl2 (400 ml) was stirred at high speed and heated to rapid reflux in a round-bottomed flask equipped with a
high-dilution adapter (Aldrich¾, Z 22,330-1) while a soln. of ethyl diazoacetate (92%; 13.4 g, 108 mmol) in
CH2Cl2 (400 ml) was added dropwise at a rate of 1/20 of the refluxing flow. After the addition was complete
(4 h), the mixture was refluxed for additional 2 h. The residue obtained after evaporation was separated by FC
(silica gel, AcOEt/petroleum ether 1 : 4): 8.15 g (47%) of syn-11 (Rf 0.31) and 8.64 g (49%) of anti-11 (Rf 0.44),
both as colorless oils.
Data of syn-11: []21D 274.1 (c 0.63, CHCl3). IR (CHCl3): 1746, 1724. 1H-NMR (500.13 MHz, CDCl3):
4.18 (q, J 7.13, MeCH2O); 2.86 (m, 1 H); 2.84 (m, 1 H); 2.09 (ddm, J 17.06, 3.50, 1 HC(7)); 2.00 (dd, J
17.06, 4.54, 1 HC(7)); 1.81 (dd, J 7.72, 7.66, HC(3)); 1.53 (ddm, J 7.72, 6.49, 1 H); 1.35 (ddm, J 7.66,
6.49, 1 H); 1.29 (t, J 7.13, MeCH2O); 1.24 (dm, J 12.65, 1 HC(8)); 1.16 (dm, J 12.65, 1 HC(8)).
13C-NMR (50.3 MHz, CDCl3): 212.92 (C(6)); 171.09 (CO); 61.03 (MeCH2O); 48.40 (C(5)); 44.39 (C(7)); 34.97
(C(1)); 27.65 (C(8)); 25.81 (C(3)); 23.17 (C(2)); 16.23 (C(4)); 13.97 (MeCH2O). CI-MS (CH4): 223 (7, [M
29]), 196 (12, [M 2]), 195 (100, [M 1]), 177 (2), 167 (5), 166 (5), 149 (47), 121 (22), 95 (4), 93 (3), 79 (5).
Anal. calc. for C11H14O3: C 68.02, H 7.27; found: C 67.96, H 7.31.
Data of anti-11: []20D 303.9 (c 0.80, CHCl3). IR (CHCl3): 1744, 1724. 1H-NMR (500.13 MHz, CDCl3):
4.13 (q, J 7.14, MeCH2O); 2.70 ± 2.73 (m, HC(1), HC(5)); 2.09 (dd, J 2.60, 2.46, HC(3)); 2.05 ± 2.03
(m, 2 HC(7)); 1.75 (dm, J 7.20, 1 H); 1.57 (dm, J 7.00, 1 H); 1.30 (m, 1 HC(8)); 1.26 (t, J 7.14,
3MeCH2O); 1.21 (dm, J 11.81, 1 HC(8)).13C-NMR (50.3 MHz, CDCl3): 212.68 (C(6)); 171.95 (CO); 60.73
(MeCH2O); 48.05 (C(5)); 43.28 (C(7)); 34.48 (C(1)); 26.94 (C(8)); 26.07 (C(2)); 19.95 (C(3)); 19.59 (C(4));
14.17 (MeCH2O). CI-MS (CH4): 223 (10, [M 29]), 195 (100, [M 1]), 194 (19,M), 166 (11), 165 (2), 149
(52), 121 (13), 93 (3), 79 (3). EI-MS: 195 (2, [M 1]), 194 (11,M), 166 (14), 165 (6), 149 (10), 148 (20), 121
(26), 120 (48), 119 (23), 93 (33), 91 (68), 79 (100), 78 (40), 77 (72), 65 (18), 51 (20), 39 (42). Anal. calc. for
C11H14O3: C 68.02, H 7.27; found: C 67.63, H 7.27.
Ethyl 5-Oxobicyclo[2.2.1]heptane-2-acetate (rac-12a) and Ethyl 6-Oxobicyclo[2.2.1]heptane-2-acetate (rac-
12b). A soln. of racemic syn-11 (550 mg, 2.83 mmol) in MeOH (30 ml) was hydrogenated at r.t./1 atm over 10%
Pd/C (204 mg) for 40 h. Then the catalyst was filtered off, the filtrate evaporated, and the residue subjected to
CC (silica gel, AcOEt/petroleum ether 1 : 16): 250 mg (45%) of rac-12a and 233.3 mg (42%) of rac-12b as
colorless oils.
Data of rac-12a : 1H-NMR (500.13 MHz, CDCl3): 4.18 (q, J 7.16, MeCH2O); 2.59 (m, 1 H); 2.46 (m, 1 H);
2.44 (dd, J 15.49, 8.00, 1 H); 2.33 (dd, J 15.49, 7.58, 1 H); 2.19 (ddd, J 15.92, 7.96, 4.92, 1 H); 2.11 (dd, J
17.85, 4.63, 1 H); 1.98 (ddd, J 17.85, 3.56, 0.97, 1 H); 1.84 (ddd, J 13.30, 8.32, 1.41, 1 H); 1.70 ± 1.68 (m, 2 H);
1.40 (ddd, J 13.30, 4.80, 4.80, 1 H); 1.27 (t, J 7.16, MeCH2O). 13C-NMR (50.3 MHz, CDCl3): 217.07 (C(5));
172.22 (CO); 60.45 (MeCH2O); 50.25 (C(4)); 45.37 (C(6)); 40.87 (CH2COOEt); 40.03 (C(2)); 36.57 (C(1));
34.57, 31.54 (C(3), C(7)); 14.22 (MeCH2O). CI-MS (CH4): 237 (4, [M 41]), 225 (14, [M 29]), 198 (14,
[M 2]), 197 (100, [M 1]), 169 (6), 168 (4), 151 (10), 123 (4).
Data of rac-12b : 1H-NMR (500.13 MHz, CDCl3): 4.14 (q, J 7.16, MeCH2O); 2.70 (m, HC(2)); 2.44 ±
2.26 (m, 4 H); 2.06 (dm, J 17.84, 1 H); 1.86 (dd, J 17.84, 3.96, 1 H); 1.82 (ddd, J 12.57, 7.48, 2.15, 1 H); 1.72
(dm, J 11.12, 1 H, HC(7)); 1.67 (dm, J 11.12, 1 HC(7)); 1.40 (dm, J 12.57, 1 H); 1.26 (t, J 7.16,
MeCH2O). 13C-NMR (50.3 MHz, CDCl3): 216.52 (C(6)); 171.76 (CO); 60.53 (MeCH2O); 54.60 (C(1)); 44.22
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(C(5)); 39.82 (CH2COOEt); 35.78 (C(4)); 35.63, 34.62 (C(3), C(7)); 32.94 (C(2)); 14.20 (MeCH2O). CI-MS
(CH4): 237 (4, [M 41]), 225 (12, [M 29]), 198 (11, [M 2]), 197 (97, [M 1]), 179 (4), 169 (5), 168 (18),
153 (14), 152 (13), 150 (100), 123 (4), 79 (3).
Methyl (1R,5R,6R)-2-Oxa-3-oxobicyclo[3.2.1]octane-6-acetate (13a). Amixture of 43 (200 mg, 86.8 mmol)
and Pb3O4 (3 mg) was heated at 190 ± 200/200 mbar for 1 h. Then the mixture was bulb-to-bulb distilled at
0.1 mbar, and the thus obtained crude product (155 mg, 90%) was recrystallized from hexane/Et2O: 110 mg
(64%) of 13a. Colorless crystals. M.p. 78 ± 79.5. []20D 18.0 (c 0.521, CHCl3). 1H-NMR (CDCl3): 4.85
(m, HC(1)); 3.69 (s, MeO); 2.75 (dd, J 18.50, 5.02, 1 HC(4)); 2.61 (ddd, J 18.62, 2.06, 2.06, 1 HC(4));
2.53 ± 2.42 (m, CH2); 2.40 ± 2.25 (m, 1 HC(7), HC(6), HC(5)); 1.94 (dm, J 13.13, 1 HC(8)); 1.79
(dm, J 13.14, 1 HC(8)); 1.55 ± 1.47 (m, 1 HC(7)). 13C-NMR (APT): 172.76, 170.21, (2 CO); 81.30 (C(1));
52.11 (MeO); 41.24, 40.68, 40.19 (C(4), C(7), C(8)); 39.05 (C(5)); 37.37 (C(6)); 33.66 (CH2). EI-MS: 199 (37,
[M 1]), 181 (100), 167 (16), 153 (17), 139 (28). HR-ESI-MS: 221.0783 ([MNa] , C10H14O4Na ; calc.
221.0784).
Benzyl (1R,5R,6R)-2-Oxa-3-oxobicyclo[3.2.1]octane-6-acetate (13b). A soln. of benzyl alcohol (11 mg,
0.10 mmol) in dry THF (3 ml) was cooled to 0 before 1.6 BuLi in hexane (65 l) was added. After 10 min
stirring, the mixture was added dropwise to a stirred soln. of 13a (20 mg, 0.10 mmol) in dry THF (5 ml) at 0.
Stirring was continued for 2 h at 0 before the mixture was poured into H2O (50 ml) and extracted with CH2Cl2.
The combined org. phase was dried (Na2SO4) and evaporated and the residue purified by prep. TLC (AcOEt/
hexane 1 :1): 7.5 mg (27%) of 13b. Colorless oil. 1H-NMR (CDCl3): 7.40 ± 7.31 (m, 5 arom. H); 5.14 (A of
AB, J 12.21, 1 H, PhCH2); 5.10 (B of AB, J 12.21, 1 H, PhCH2); 4.83 (m, HC(1)); 2.71 (dd, J 18.62, 4.89,
1 HC(4)); 2.56 (ddd, J 18.61, 2.14, 2.14, 1 HC(4)); 2.52 ± 2.43 (m, CH2); 2.42 ± 2.22 (m, 1 HC(7),
HC(6) , HC(5)) ; 1.91 (dm, J 13.12, 1 HC(8)) ; 1.76 (dm, J 13.13, 1 HC(8)) ; 1.55 ± 1.45
(m, 1 HC(7)). 13C-NMR (APT): 171.73, 169.86 (2 CO); 135.63 (arom. C); 128.67, 128.57, 128.48, 128.37,
128.27 (5 arom. CH), 80.95 (C(1)); 66.54 (PhCH2); 40.89, 40.64, 39.86 (C(4), C(7), C(8)); 38.79 (C(5)); 37.02
(C(6)); 33.33 (CH2). HR-ESI-MS: 297.1093 ([MNa] , C16H18O4Na ; calc. 297.1097).
(1R,5R,6R)-2-Oxa-3-oxobicyclo[3.2.1]octane-6-acetic Acid (13c) . A stirred soln. of 13b (7.5 mg,
0.027 mmol) in AcOEt (1 ml) was hydrogenated over 10% Pd/C (2 mg) at r.t./1 atm until the uptake of H2
ceased (1 h). The catalyst was filtered off, the filtrate evaporated, and the residue recrystallized from Et2O/
hexane: 3 mg (60%) of 13c. Colorless crystals. M.p. 123 ± 125. 1H-NMR (CDCl3): 10.3 (br. s, COOH); 4.86
(m, HC(1)); 2.76 (dd, J 18.58, 4.89, 1 HC(4)); 2.62 (ddd, J 18.58, 1.96, 1.96, 1 HC(4)); 2.56 ± 2.45
(m, CH2); 2.43 ± 2.28 (m, 1 HC(7), HC(6), HC(5)); 1.96 (dm, J 13.20, 1 HC(8)); 1.80 (dm, J 13.20,
1 HC(8)); 1.57 ± 1.50 (m, 1 HC(7)). 13C-NMR (APT): 176.88 (COOH); 169.88 (CO); 80.91 (C(1)); 40.89,
40.09, 39.88 (C(4), C(7), C(8)); 38.47 (C(5)); 37.06 (C(6)); 33.32 (CH2). HR-ESI-MS: 207.0622 ([MNa] ,
C9H12O4Na ; calc. 207.0627).
(1R,5R,6R)-6-(2-Hydroxyethyl)-2-oxabicyclo[3.2.1]octan-3-one (14). a) A soln. of 13c (3 mg, 0.016 mmol)
in dry THF (2 ml) was cooled to 0 before 1 BH3 in THF (70 l) was added. The mixture was stirred for 7 h at
0, then diluted with H2O (1 ml) and shaken with CH2Cl2 (10 ml). The org. layer was dried (Na2SO4) and
evaporated, and the residue purified by prep. TLC (AcOEt/hexane/EtOH 10 :10 :1): 1.3 mg (47%) of 14).
Colorless oil.
b) A mixture of 30, (5.18 g, 33.6 mmol), NaHCO3 (5.65 g, 67.2 mmol), and ca. 55% MCPBA (21.14 g,
67.2 mmol) in CH2Cl2 (460 ml) was stirred at r.t. until the starting material had completely disappeared (ca. 2 h,
TLC monitoring). The mixture was then filtered, the solid washed with CH2Cl2, and the combined filtrate
shaken several times with small volumes of cold 10% aq. Na2SO3 soln. until the starch/I2 test of the org. layer was
negative. Then the combined aq. phase was extracted with CH2Cl2 (6 100 ml), the combined org. soln. dried
(Na2SO4) and evaporated, and the residue purified by CC (AcOEt/CH2Cl2/EtOH 10 :10 : 1): 4.92 g (86%) of 14.
Rf 0.39. Colorless oil. []20D 31.9 (c 1.88, CHCl3). IR (CHCl3): 1726. 1H-NMR (CDCl3): 4.85 (m, HC(1));
3.72 ± 3.62 (m, CH2CH2OH); 2.74 (dd, J 18.48, 5.03, 1 HC(4)); 2.55 (ddd, J 18.57, 2.09, 2.09, 1 HC(4));
2.44 (ddd, J 14.91, 8.60, 2.65, 1 HC(7)); 2.27 (m, HC(5)); 2.14 (m, HC(6)); 1.93 (dm, J 13.08,
1 HC(8)); 1.80 (dm, J 13.00, 1 HC(8)); 1.68 (m, 1 H, CH2CH2OH); 1.58 (br. s, 1 H, CH2CH2OH);
1.55 ± 1.47 (m, 2 H, 1 HC(7), CH2CH2OH). 13C-NMR (APT): 170.25 (CO); 81.14 (C(1)) ; 61.18
(CH2CH2OH); 41.17 (C(4)); 40.27 (CH2CH2OH); 39.30 (C(7)); 39.04 (C(6)); 37.08 (C(5)); 33.48 (C(8)). EI-
MS: 171 (23, [M 1]), 153 (63), 135 (21), 125 (24), 111 (100), 107 (27), 93 (49), 81 (10), 79 (10), 67 (6), 61
(10). HR-ESI-MS: 193.0836 ([MNa] , C9H14O3Na ; calc. 193.0835).
Methyl (1R,2S,4S)-4-Hydroxy-2-(2-hydroxyethyl)cyclopentaneacetate (15a). A soln. of 14 (5.8 g, 34 mmol)
inMeOH (200 ml) containing 37% aq. HCl soln. (1.9 ml, 23 mmol) was refluxed for 20 h and then cooled, before
10% aq. NaHCO3 soln. (40 ml) was added. The resulting mixture was extracted with AcOEt (8 100 ml), the
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combined org. extract dried (Na2SO4) and evaporated, and the slightly yellow oil (6.19 g, ca. 90%) was used
without further purification for the next step. 1H-NMR (500.13 MHz, CDCl3): 4.34 (m, HC(4)); 3.74 ± 3.61
(m, HOCH2CH2OH); 3.68 (s, MeO); 2.60 (dd, J 15.66, 4.86, 1 H, CH2CO2Me); 2.36 (dd, J 15.66, 8.18, 1 H,
CH2CO2Me); 2.29 (ddd, J 14.02, 8.51, 6.01, 1 H); 1.99 ± 1.93 (m, 2 H); 1.91 (m, 1 H); 1.79 (m, 1 H); 1.68 (br.,
2 OH); 1.49 ± 1.40 (m, 2 H); 1.37 (dddd, J 13.96, 7.08, 3.48, 1.67, 1 H). 13C-NMR (50.3 MHz, CDCl3): 173.88
(CO); 72.50 (C(4)); 61.75 (CH2CH2OH); 51.51 (MeO); 42.34, 41.62 (C(3), C(5)); 40.55, 39.61 (C(1), C(2));
39.20 (CH2CH2OH); 37.46 (CH2CO2Me). CI-MS (CH4): 231 (13, [M 29]), 217 (1, [M 15]), 203 (17, [M
1]), 201 (2, [M 1]), 185 (47), 171 (7), 168 (13), 167 (100), 153 (87), 135 (47), 125 (16), 111 (56), 107 (34), 93
(26).
Methyl (1R,2S,4S)-2-{2-{[(tert-Butyl)diphenylsilyl]oxy}ethyl}-4-hydroxycyclopentaneacetate (15b). A soln.
of 15a (6.27 g, 31 mmol) in anh. DMF (60 ml) containing 1H-imidazole (5.28 g, 77.5 mmol), and (tert-
butyl)chlorodiphenylsilane (10.23 g, 37.2 mmol) was stirred for 40 h at r.t. and then poured into AcOEt (1.2 l).
The resulting soln. was shaken successively with 1 HCl (12 ml), H2O (120 ml) and sat. aq. NaHCO3 soln.
(120 ml), dried (Na2SO4) and evaporated and the residue purified by FC (AcOEt/CH2Cl2 1 :8): 11.1 g (74%
from 15a) of 15b (Rf 0.44). Colorless syrup. []23D 27.1 (c 0.78, CHCl3). IR (CHCl3): 1728. 1H-NMR
(360 MHz, CDCl3): 7.68 ± 7.63 (m, 4 arom. H); 7.46 ± 7.35 (m, 6 arom. H); 4.27 (m, HC(4)); 3.74 ± 3.59
(m, CH2CH2O); 3.66 (s, MeO); 2.56 (dd, J 15.75, 4.36, 1 H, CH2CO2Me); 2.34 ± 2.21 (m, 2 H); 1.96 ± 1.74
(m, 4 H); 1.67 (br., OH); 1.41 ± 1.29 (m, 3 H); 1.04 (s, tBu). 13C-NMR (50.3 MHz, CDCl3): 173.68 (CO); 135.51,
133.91, 129.52, 127.56 (12 arom. C); 72.38 (C(4)); 62.85 (CH2CH2O); 51.37 (MeO); 42.25, 41.56 (C(3), C(5));
40.63, 39.66 (C(1), C(2)); 39.02 (CH2CH2OH); 37.23 (CH2CO2Me); 26.83 (Me3C); 19.11 (Me3C). FAB-MS: 463
(6, [MNa]), 441 (7, [M 1]), 423 (2), 383 (56), 363 (22), 345 (20), 319 (4), 305 (3), 273 (8), 253 (7), 239
(11), 213 (73), 199 (100), 183 (52), 167 (60), 153 (36), 135 (100), 121 (50). Anal. calc. for C26H36O4Si: C 70.87,
H 8.23; found: C 71.14, H 8.03.
Ethyl (1R,2R,3R,4R,5R)- and (1R,2R,3S,4R,5R)-Spiro[1,3-dioxolane-2,6-tricyclo[3.2.1.02,4]octane]-
3-carboxylate (syn- and anti-21). A soln. of 20 (83.70 g, 0.55 mol; []23D 168.2 (c 0.85, CHCl3); prepared
like the racemate [30] [31]) in dry, freshly distilled CH2Cl2 (750 ml) was treated in the presence of [Pd(OAc)2]
(1.23 g, 5.54 mmol) with a soln. of 92% ethyldiazoacetate 81.90 g, 0.66 mol) diluted to 750 ml with CH2Cl2 under
the same conditions as described for 11. After the addition was complete (7 h), the mixture was refluxed for
additional 2 h. The residue obtained after evaporation was separated by FC (silica gel, AcOEt/petroleum ether
1 : 8): 58.98 g (45%) of syn-21 (Rf 0.24) and 68.15 g (52%) of anti-21 (Rf 0.27).
Data of syn-21: Colorless solid. M.p. 47.5 ± 49.5. []23D 6.2 (c 0.78, CHCl3). IR (CHCl3): 1723.
1H-NMR (500.13 MHz, CDCl3): 4.14 (q, J 7.14, MeCH2O); 3.97 ± 3.86 (m, 4 H, OCH2CH2O); 2.53
(m, HC(1)); 2.43 (m,HC(5)); 1.83 (dd, J 12.90, 4.05, 1 HC(7)); 1.61 (dd, J 12.90, 3.84, 1 HC(7));
1.57 (dd, J 7.96, 7.96, HC(3)); 1.48 (ddm, J 7.96, 6.72, HC(4)); 1.30 (ddm, J 7.96, 6.72, HC(2)); 1.27
(t, J 7.14,MeCH2O); 1.20 (dm, J 12.35, 1 HC(8)); 0.81 (dm, J 12.35, 1 HC(8)). NOE: 2.53 (8.03, 1.83),
1.61 (16.15, 1.83), 1.48 (2.08, 1.57), 1.30 (5.04, 1.57), 2.43 (3.63, 1.48), 1.57 (4.34, 1.48), 1.30 (4.35, 1.48), 1.57
(5.50, 1.30), 1.48 (4.48, 1.30), 2.53 (0.65, 1.20), 2.43 (0.97, 1.20), 0.81 (12.41, 1.20), 2.53 (2.57, 0.81), 2.43 (3.93,
0.81), 1.20 (25.47, 0.81). 13C-NMR (50.3 MHz, CDCl3): 172.17 (CO); 117.17 (C(6)); 64.59, 64.01 (OCH2CH2O);
60.69 (CH2O); 43.51 (C(7)); 43.04 (C(5)); 35.47 (C(1)); 28.16 (C(8)); 23.82 (C(3)); 22.19 (C(2)); 16.65
(C(4)); 14.03 (Me). CI-MS (CH4): 267 (7, [M 29]), 239 (52, [M 1]), 238 (6,M), 193 (100), 177 (7), 165
(6), 149 (10), 131 (1), 121 (4), 105 (3), 73 (7). Anal. calc. for C13H18O4: C 65.53, H 7.61; found: C 65.70, 7.66.
Data of anti-21: Colorless oil. []22D 54.6 (c 0.80, CHCl3). IR (CHCl3): 1719. 1H-NMR (500.13 MHz,
CDCl3): 4.10 (q, J 7.12, MeCH2O); 3.98 ± 3.83 (m, OCH2CH2O); 2.39 (m, HC(1)); 2.29 (m, HC(5)); 1.78
(dd, J 12.79, 4.00, HC(7)); 1.77 (dd, J 2.58, 2.58, HC(3)); 1.70 (dm, J 7.26, HC(4)); 1.65 (dd, J
12.79, 3.71, 1 HC(7)) ; 1.54 (dm, J 7.26, HC(2)) ; 1.24 (t, J 7.12, MeCH2O); 1.15 (dm, J 11.33,
1 HC(8)); 0.98 (dm, J 11.33, 1 HC(8)). NOE: 1.78 (5.13, 2.39), 1.54 (3.54, 2.39), 1.70 (4.41, 2.29), 2.39
(4.47, 1.78), 1.65 (18.89, 1.78), 2.29 (3.04, 1.70), 1.54 (3.44, 1.70), 2.39 (2.36, 1.65), 2.39 (3.18, 1.54), 2.39 (3.24,
1.15), 2.29 (3.21, 1.15), 0.97 (28.24, 1.15), 2.39 (2.64, 0.98), 1.77 (23.51, 0.98), 1.15 (25.71, 0.98). 13C-NMR
(50.3 MHz, CDCl3): 173.12 (CO); 116.89 (C(6)); 64.63, 64.00 (OCH2CH2O); 60.30 (CH2O); 43.00 (C(5)); 42.79
(C(7)); 35.14 (C(1)); 27.42 (C(8)); 25.75 (C(2)); 20.69 (C(4)); 18.80 (C(3)); 14.29 (Me). CI-MS (CH4): 267 (8,
[M 29]), 239 (69, [M 1]), 238 (14,M), 193 (100), 165 (6), 149 (6), 112 (5), 99 (7), 87 (27), 73 (18). Anal.
calc. for C13H18O4: C 65.53, H 7.61; found: C 65.68, H 7.76.
(1R,2R,3R,4S,5R)-Spiro[1,3-dioxolane-2,6-tricyclo[3.2.1.02,4]octane]-3-methanol (syn-25a). A soln. of
syn-21 (54.8 g, 0.23 mol) in dry Et2O (200 ml) was added dropwise over 2 h to an ice-cooled suspension of
LiAlH4 (8.73 g, 0.23 mol) in dry Et2O (600 ml), and the mixture was stirred at r.t. for 24 h. Thereafter, the excess
LiAlH4 was decomposed by very slow addition of H2O before the soln. was filtered. The aq. layer was extracted
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with AcOEt (4 100 ml), the combined org. extract washed with brine (2 100 ml), dried (Na2SO4); and
evaporated, and the residue purified by CC (AcOEt/CH2Cl2 1 :1): 41.98 g (93%) of syn-25a (Rf 0.39). Colorless
oil. []24D 16.5 (c 0.71, CHCl3). 1H-NMR (360 MHz, CDCl3): 3.97 ± 3.85 (m, OCH2CH2O, CH2OH); 2.43
(m, HC(1)); 2.35 (m, HC(5)); 1.82 (dd, J 12.55, 4.00, 1 HC(7)); 1.61 (dd, J 12.55, 3.71, 1 HC(7));
1.43 (br. s, OH); 1.25 (ddm, J 7.70, 7.42, HC(3)); 1.20 (dm, J 11.69, 1 HC(8)); 1.11 ± 1.04 (m, HC(2),
HC(4)); 0.98 (dm, J 11.69, 1 HC(8)) . 13C-NMR (50.3 MHz, CDCl3): 117.50 (C(6)) ; 64.42, 63.78
(OCH2CH2O); 60.63 (CH2OH); 43.83 (C(7)); 43.13 (C(5)); 35.44 (C(1)); 29.22 (C(8)); 25.01 (C(3)); 22.20
(C(2)); 16.08 (C(4)). CI-MS (CH4): 198 (5, [M 2]), 197 (40, [M 1]), 196 (1, M), 195 (5, [M 1]), 180
(11), 179 (100), 153 (4), 135 (2), 118 (1), 117 (12), 99 (2), 87 (20), 86 (12), 73 (7). Anal. calc. for C11H16O3:
C 67.32, H 8.22; found: C 67.09, H 8.14.
(1R,2R,3S,4R,5R)-Spiro[1,3-dioxolane-2,6-tricyclo[3.2.1.02,4]octane]-3-methanol (anti-25a). As de-
scribed for syn-25a, with anti-21 (59.6 g, 0.25 mol): anti-25a (46.12 g, 94%). Colorless oil. Rf 0.33: []24D 
31.1 (c 0.37, CHCl3). 1H-NMR (500.13 MHz, CDCl3): 3.97 ± 3.85 (m, OCH2CH2O); 3.43 (dd, J 11.00,
7.05, 1 H, CH2OH); 3.39 (dd, J 11.00, 7.15, 1 H, CH2OH); 2.33 (m, HC(1)); 2.24 (m, HC(5)); 1.77
(dd, J 12.80, 4.05, 1 HC(7)); 1.58 (dd, J 12.80, 3.65, 1 HC(7)); 1.45 (br. s, OH); 1.33 (m, HC(3)); 1.11
(dm, J 11.10, 1 HC(8)); 1.03 (dm, J 11.10, 1 HC(8)); 0.99 (dm, J 7.15, HC(4)); 0.83 (dm, J 7.15,
HC(2)). 13C-NMR (50.3 MHz, CDCl3): 117.08 (C(6)); 64.78, 64.30 (OCH2CH2O); 63.72 (CH2OH); 43.26
(C(7)); 42.73 (C(5)); 34.86 (C(1)); 27.28 (C(8)); 20.99 (C(3)); 19.02 (C(2)); 15.20 (C(4)). CI-MS (CH4): 198
(4, [M 2]), 197 (35, [M 1]), 196 (1,M), 195 (7, [M 1]), 180 (11), 179 (100), 153 (4), 135 (4), 117 (14),
99 (2), 87 (14). Anal. calc. for C11H16O3: C 67.32, H 8.22; found: C 67.06, H 8.49.
S-Methyl O-[(1R,2R,3R,4R,5R)-Spiro[1,3-dioxolane-2,6-tricyclo[3.2.1.02,4]octane]-3-yl] Carbonodi-
thioate (syn-25b). To a soln. of syn-25a (42.00 g, 0.214 mol) and DBN (53.16 g, 0.43 mol) in dry MeCN
(150 ml), CS2 (40 ml) was added, and the mixture was stirred for 2 h at r.t. Thereafter, MeI (78 ml) was added,
and stirring was continued for a further 3 h at r.t. before the excess reactants and most of the solvent were
evaporated to yield an oily residue, which was poured into H2O (200 ml) and extracted with AcOEt (4
150 ml). The combined org. extract was washed with brine (100 ml), dried (Na2SO4), and evaporated and the
residue purified by CC (AcOEt/petroleum ether 1 : 8): 58.84 g (96%) of syn-25b (Rf 0.5). Yellow oil. []25D 
1.4 (c 0.84, CHCl3). IR (CHCl3): 1198s, 1080vs, 1065s. 1H-NMR (200 MHz, CDCl3): 4.84 (d, J 5.86,
CH2O); 3.98 ± 3.85 (m, OCH2CH2O); 2.57 (s, MeS); 2.48 (m, HC(1)); 2.36 (m, HC(5)); 1.83 (dd, J 12.47,
3.99, 1 HC(7)) ; 1.60 (dd, J 12.47, 3.71, 1 HC(7)) ; 1.40 ± 1.08 (m, HC(2), HC(3), HC(4),
1 HC(8)); 0.88 (dm, J 11.91, 1 HC(8)). 13C-NMR (50.3 MHz, CDCl3): 215.24 (CS); 117.11 (C(6));
72.45 (CH2O); 64.33, 63.72 (OCH2CH2O); 43.59 (C(7)); 42.89 (C(5)); 35.18 (C(1)); 29.10 (C(8)); 22.44
(MeS); 20.14 (C(2)); 18.74 (C(3)); 16.58 (C(4)). CI-MS (CH4): 288 (2, [M 2]), 287 (15, [M 1]), 285 (2,
[M 1]), 243 (4), 239 (4), 211 (2), 181 (3), 180 (21), 179 (100), 167 (1), 135 (5), 119 (6), 118 (4), 118 (34), 99
(7), 93 (8), 91 (7), 87 (12), 73 (8), 41 (8). Anal. calc. for C13H18O3S2: C 54.52, H 6.33, S 22.39; found: C 54.72,
H 6.48, S 22.51.
S-Methyl O-[(1R,2R,3S,4R,5R)-Spiro[1,3-dioxolane-2,6-tricyclo[3.2.1.02,4]octane]-3-yl] Carbonodi-
thioate (anti-25b): As described for syn-25b, with anti-25a (46.12 g, 0.235 mol): anti-25b (64.61 g, 96%). Slightly
yellow oil. Rf 0.5. []25D 26.6 (c 0.73, CHCl3). IR (CHCl3): 1196m, 1098m, 1063s. 1H-NMR (200 MHz,
CDCl3): 4.43 (dd, J 11.29, 7.42, 1 H, CH2O); 4.36 (dd, J 11.29, 7.42, 1 H, CH2O); 3.99 ± 3.81 (m, OCH2-
CH2O); 2.57 (s, MeS); 2.37 (m, HC(1)); 2.27 (m, HC(5)); 1.78 (dd, J 12.77, 4.00, 1 HC(7)); 1.60
(dd, J 12.77, 3.22, 1 HC(7)); 1.57 ± 1.45 (m, 1 H); 1.19 ± 0.94 (m, 4 H). 13C-NMR (50.3 MHz, CDCl3): 216.09
(CS); 117.09 (C(6)); 76.36 (CH2O); 64.56, 63.99 (OCH2CH2O); 43.31 (C(7)); 42.90 (C(5)); 35.01 (C(1)); 27.34
(C(8)); 21.68 (C(2)); 19.06 (MeS); 16.13 (C(3)); 14.92 (C(4)). CI-MS (CH4): 288 (2, [M 2]), 287 (11, [M
1]), 286 (2,M), 285 (2, [M 1]), 271 (1), 239 (2), 211 (1), 180 (18), 179 (100), 135 (1), 119 (2), 117 (11), 99
(3), 91 (1), 87 (3). Anal. calc. for C13H18O3S2: C 54.52, H 6.33, S 22.39; found: C 54.74, H 6.23, S 22.38.
(1RS,2RS,3RS,4RS,5RS)-3-(Hydroxymethyl)tricyclo[3.2.1.02,4]octan-6-one (rac-syn-26a). A soln. of rac-
syn-25a (2.94 g, 15 mmol) in AcOH/H2O 3 :7 (20 ml) was stirred for 1 d at r.t. The mixture was then carefully
neutralized adding dropwise 10% aq. NaOH soln., and the aq. phase was extracted with AcOEt (4 100 ml).
The combined extracts were washed with brine (2 50 ml), dried (Na2SO4), and evaporated and the residue
purified by FC (AcOEt/CH2Cl2 1 :1): rac-syn-26a (2.15 g, 94%). Colorless oil. IR (CHCl3): 1740. 1H-NMR
(200 MHz, CDCl3): 3.98 ± 3.92 (m, CH2OH); 2.81 ± 2.73 (m, 2 HC(1), HC(5)); 2.14 ± 1.91 (m, 2 HC(7));
1.80 (br. s, OH); 1.37 ± 1.22 (m, 2 HC(8), HC(3), HC(4)); 1.12 (dm, J 7.08, HC(2)). 13C-NMR
(50.3 MHz, CDCl3): 213.93 (C(6)); 59.33 (CH2OH); 48.03 (C(5)); 44.25 (C(7)); 34.36 (C(1)); 28.30 (C(8)); 27.28
(C(3)); 23.24 (C(2)); 15.10 (C(4)). CI-MS (CH4): 193 (4, [M 41]), 181 (9, [M 29]), 154 (9, [M 2]), 153
(100, [M 1]), 135 (31), 117 (14), 109 (25), 107 (47), 95 (10), 93 (39), 79 (21), 61 (14), 55 (7), 43 (7), 41 (35).
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(1RS,2RS,3SR,4RS,5RS)-3-(Hydroxymethyl)tricyclo[3.2.1.02,4]octan-6-one (rac-anti-26a). As described
for rac-syn-26a, with rac-anti-25a (2.36 g, 12 mmol); rac-anti-26a (1.74 g, 95%). Colorless oil. IR (CHCl3):
1742. 1H-NMR (500.13 MHz, CDCl3): 3.48 (dd, J 11.28, 6.92, 1 H, CH2OH); 3.45 (dd, J 11.28, 6.92, 1 H,
CH2OH); 2.66 (m, HC(1)); 2.64 (m, HC(5)); 2.03 (dd, J 16.78, 3.54, 1 HC(7)); 1.97 (dd, J 16.78, 4.23,
1 HC(7)); 1.85 (m, CH2OH); 1.66 (m, HC(3)); 1.34 (dm, J 11.60, HC(8)); 1.17 (dm, J 11.60,
1 HC(8)); 1.10 (dm, J 6.95, HC(4)); 0.89 (dm, J 6.95, HC(2)). 13C-NMR (50.3 MHz, CDCl3): 214.24
(C(6)); 64.14 (CH2OH); 48.07 (C(5)); 44.32 (C(7)); 34.43 (C(1)); 26.80 (C(8)); 22.15 (C(3)); 20.77 (C(2)); 14.87
(C(4)). CI-MS (CH4): 193 (3, [M 41]), 181 (6, [M 29]), 154 (10, [M 2]), 153 (100, [M 1]), 152 (9,
M), 135 (66), 117 (17), 107 (56), 79 (15), 55 (2).
S-Methyl O-[(1RS,2RS,3RS,4RS,5RS)-6-Oxotricyclo[3.2.1.02,4]oct-3-yl] Carbonodithioate (rac-syn-26b).
To a soln. of rac-syn-26a (883 mg, 5.80 mmol) and DBN (1.44 g, 11.6 mmol) in dry MeCN (20 ml), CS2 (3 ml)
was added, and the mixture was stirred for 1 h at r.t. After addition of MeI (7 ml), stirring was continued for a
further 90 min at r.t. The solvent was evaporated, the residue diluted with H2O (25 ml) and extracted with
AcOEt (4 25 ml), the combined org. extract washed with brine (25 ml), dried (Na2SO4), and evaporated, and
the residue purified by CC (AcOEt/petroleum ether 1 :8): rac-syn-26b (1.27 mg, 90%). Yellow oil. 1H-NMR
(200 MHz, CDCl3): 4.93 (dd, J 11.57, 6.25, 1 H, CH2O); 4.85 (dd, J 11.57, 5.91, 1 H, CH2O); 2.84 ± 2.76
(m, HC(1), HC(5)); 2.58 (s, MeS); 2.08 ± 1.98 (m, 2 HC(7)); 1.62 ± 1.14 (m, HC(2), HC(3), HC(4),
2 HC(8)). 13C-NMR (50.3 MHz, CDCl3): 215.67, 213.05 (CO, CS); 71.61 (CH2O); 48.40 (C(5)); 44.58 (C(7));
34.90 (C(1)); 28.88 (C(8)); 24.12 (C(2)); 23.27 (C(3)); 19.05 (MeS); 16.29 (C(4)). CI-MS (CH4): 271 (3, [M
29]), 263 (11), 245 (10, [M 3]), 244 (11, [M 2]), 243 (100, [M 1]), 215 (9), 195 (23), 167 (35), 153 (6),
151 (3), 136 (8), 135 (60), 117 (27), 107 (61), 93 (40), 91 (21), 79 (24), 75 (9), 41 (42).
S-Methyl O-[(1RS,2RS,3SR,4RS,5RS)-3-Oxotricyclo[3.2.1.02,4]oct-3-yl] Carbonodithioate (rac-anti-26b).
As described for rac-syn-26b, with rac-anti-26b, (535 mg, 3.51 mmol): rac-anti-26b (762 mg, 90%). Yellow solid.
M.p. 73 ± 75. IR (CHCl3): 1746. 1H-NMR (200 MHz, CDCl3): 4.41 (d, J 7.22, CH2O); 2.69 ± 2.63 (m, HC(1),
HC(5)); 2.55 (s, MeS); 2.04 ± 1.93 (m, 2 HC(7)); 1.82 (m, HC(3)); 1.39 ± 0.97 (m, HC(2), HC(3),
2 HC(8)). 1H-NMR (50.3 MHz, CDCl3): 215.95, 213.40 (CO, CS); 74.77 (CH2O); 47.93 (C(5)); 44.01 (C(7));
34.35 (C(1)); 26.60 (C(8)); 22.53 (C(2)); 19.08 (MeS); 16.53 (C(3)); 15.43 (C(4)). CI-MS (CH4): 271 (4, [M
29]), 263 (18), 245 (11, [M 3]), 244 (19), 243 (100, [M 1]), 214 (6), 195 (12), 167 (7), 151 (4), 136 (14),
135 (98), 117 (42), 107 (70), 93 (66), 91 (24), 79 (16), 75 (7), 55 (8), 41 (35).
(1RS,4RS,6RS)-6-Ethenylbicyclo[2.2.1]heptan-2-one (rac-27a) and (1RS,4RS,5RS)-5-Ethenylbicy-
clo[2.2.1]heptan-2-one (rac-27b). To a soln. of rac-syn or rac-anti-26b (651 mg, 2.69 mmol) in toluene
(30 ml), Bu3SnH (1.07 ml, 4.04 mmol) and AIBN (89 mg, 0.54 mmol) were added. The soln. was purged of air
by bubbling N2 for 2 h and thereafter heated at 100 (oil-bath temp.) for 5 h. After evaporation, the residue was
purified by CC (silica gel (230 ± 430 mesh), AcOEt/petroleum ether 1 : 16): rac-27a/rac-27b 1 :0.72 (by 1H-NMR;
322 mg, 88%). Colorless oil. The isomers were separated by CC (Merck silica gel 60 (0.015 ± 0.040 mm), AcOEt/
petroleum ether 1 : 32).
Data of rac-27a (first eluted): IR (CHCl3): 1740. 1H-NMR (500.13 MHz, CDCl3): 5.78 (ddd, J 17.14, 10.53,
6.54, CH2CH); 5.18 (dm, J 17.14, 1 H, CH2CH); 5.13 (dm, J 10.53, 1 H, CH2CH); 2.62 (dm, J 6.54,
HC(6)); 2.55 ± 2.52 (m, HC(1), HC(4)); 2.18 (dm, J 17.90, 1 H); 2.02 ± 1.85 (m, 3 H); 1.51 (m, 1 H); 1.43
(m, 1 H). 13C-NMR (50.3 MHz, CDCl3): 216.55 (C(2)); 134.67 (Ch2CH); 117.04 (CH2CH); 53.82 (C(1));
51.28 (C(6)); 46.64 (C(3)); 39.46 (C(4)); 24.98, 21.52 (C(5), C(7)). CI-MS (CH4): 177 (4, [M 41]), 165 (10,
[M 29]), 138 (10, [M 2]), 137 (100, [M 1]), 136 (3,M), 135 (1, [M 1]), 123 (3), 119 (20), 109 (21),
108 (4), 107 (2), 95 (13), 94 (4), 93 (14), 91 (5), 79 (4), 67 (8), 55 (2).
Data of rac-27b : IR (CHCl3): 1734. 1H-NMR (500.13 MHz, CDCl3): 5.85 (ddd, J 17.27, 10.18, 7.22,
CH2CH); 5.05 ± 4.99 (m, CH2CH); 2.61 (m, HC(5)); 2.51 (m, HC(4)); 2.38 (m, HC(1)); 2.11 (dd, J
17.80, 4.60, 1 HC(3)); 1.91 (dd, J 17.80, 4.25 Hz, 1 HC(3)); 1.81 (ddd, J 13.28, 8.54, 2.20, 1 HC(6)); 1.74
(dm, J 10.70, 1 HC(7)); 1.68 ± 1.61 (m, 1 HC(6), 1 HC(7)). NOE: 2.11 (4.12, 2.51), 1.90 (1.53, 2.51), 2.38
(6.44, 1.81). 13C-NMR (50.3 MHz, CDCl3): 217.20 (C(2)); 142.00 (CH2CH); 113.41 (CH2CH); 50.04 (C(5));
45.09 (C(3)); 43.45 (C(1)); 40.94 (C(4)); 34.68, 30.89 (C(6), C(7)). CI-MS (CH4): 177 (6, [M 41]), 165 (6,
[M 29]), 138 (11, [M 2]), 137 (100, [M 1]), 136 (33,M), 135 (1, [M 1]), 119 (20), 118 (7), 109 (16),
108 (8), 107 (4), 95 (8), 94 (8), 93 (15), 92 (26), 91 (10), 79 (5), 67 (5).
(1R,4R)-6-Ethenylspiro[bicyclo[2.2.1]heptane-2,2-[1,3]dioxolane] (28a) and (1R,4R,5R)-5-Ethenylspiro-
[bicyclo[2.2.1]heptane-2,2-[1,3]dioxolane] (28b). As described for rac-27a/b, with syn- or anti-25b (64.61 g,
0.226 mol), dry toluene (1.5 l), Bu3SnH (120 ml, 0.452 mol), and AIBN (1.86 g, 11.3 mmol) (8 h at 120): 39.11 g
(96%) 28a/28b 1 :3.2, which were separated as described above. Further purification was achieved by CC
(Merck silica gel 60 (0.015 ± 0.040 mm), AcOEt/hexane 1 :32).
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Data of 28a (first eluted): Colorless oil. []23D 2.54 (c 0.63, CHCl3). 1H-NMR (500.13 MHz, CDCl3):
5.76 (ddd, J 17.26, 10.02, 7.41, CH2CH); 4.98 (dm, J 17.26, 1 H, CH2CH); 4.90 (dm, J 10.02, 1 H,
CH2CH); 3.96 ± 3.83 (m, OCH2CH2O); 2.70 (m, 1 HC(6)); 2.29 (m, HC(4)); 2.01 (m, HC(1)); 1.81
(ddd, J 13.13, 4.55, 3.03, 1 HC(3)); 1.60 (ddd, J 11.96, 8.93, 2.70, 1 HC(5)); 1.55 (dm, J 10.11,
1 HC(7)); 1.46 (dd, J 13.13, 3.37, 1 HC(3)); 1.41 (dm, J 10.11, 1 HC(7)); 1.36 (dm, J 11.96,
1 HC(5)). NOE: 2.01 (2.92, 2.70), 1.60 (3.34, 2.70), 1.81 (3.79, 2.29), 1.60 ± 1.36 (9.20, 2.29), 3.96 ± 3.83
(4.44, 2.01), 2.70 (3.40, 2.01), 1.55 (1.76, 2.01), 1.41 (2.07, 2.01), 2.29 (4.54, 1.81), 1.46 (17.55, 1.81), 2.70 (11.12,
1.60), 2.29 (2.37, 1.60), 1.36 (24.65, 1.60), 2.29 (3.55, 1.55), 2.01 (4.29, 1.55), 1.41 (15.31, 1.55), 2.29 (2.26, 1.46),
1.80 (17.68, 1.46), 2.70 (1.54, 1.36), 2.29 (4.64, 1.36), 1.60 (19.53, 1.36). 13C-NMR (50.3 MHz, CDCl3): 142.99
(CH2CH); 116.02 (CH2CH); 112.30 (C(2)); 64.48, 63.76 (OCH2CH2O); 49.49 (C(1)); 43.11 (C(3)); 38.62,
35.96 (C(4), C(6)); 35.90, 34.93 (C(5), C(7)). CI-MS (CH4): 209 (3, [M 29]), 182 (11, [M 2]), 181 (100,
[M 1]), 180 (45,M), 179 (18, [M 1]), 165 (1), 153 (2), 152 (2), 151 (3), 137 (5), 126 (7), 125 (4), 113 (4),
112 (4), 99 (7), 93 (7), 92 (11), 87 (4), 73 (8). HR-EI-MS (pos.): 180.1149 (C11H16O2 ; calc. 180.1145).
Data of 28b : Colorless oil. []24D 49.9 (c 1.33, CHCl3). 1H-NMR (500.13 MHz, CDCl3): 5.77 (ddd, J
17.33, 10.13, 7.35, CH2CH); 4.95 (dm, J 17.33, 1 H, CH2CH); 4.89 (dm, J 10.13, 1 H, CH2CH); 3.95 ±
3.81 (m, OCH2CH2O); 2.22 (m, HC(5)); 2.15 (m, HC(1)); 2.11 (m, HC(4)); 1.97 (ddd, J 12.80, 8.59,
2.27, 1 HC(6)); 1.85 (dd, J 13.31, 4.89, 1 HC(3)); 1.54 (dm, J 10.19, 1 HC(7)); 1.50 (dd, J 13.31, 3.40,
1 HC(3)); 1.43 (dm, J 10.19, 1 HC(7)); 1.22 (ddd, J 12.80, 4.57, 4.55, 1 HC(6)). NOE: 1.97 (3.11, 2.22),
2.22 (5.20, 1.97), 1.22 (16.05, 1.97), 2.15 (1.91, 1.54), 2.11 (1.59, 1.54), 1.43 (17.63, 1.54), 2.15 (3.59, 1.43), 2.11
(1.99, 1.43), 1.54 (14.40, 1.43), 2.22 (5.55, 1.22), 2.15 (7.70, 1.22), 1.97 (15.11, 1.22). 13C-NMR (50.3 MHz,
CDCl3): 143.57 (CH2CH); 116.02 (CH2CH); 112.20 (C(2)); 64.44, 63.82 (OCH2CH2O); 44.28, 44.17, 41.44
(C(1), C(4), C(5)); 43.85, 34.88, 29.57 (C(3), C(6), C(7)). CI-MS (CH4): 209 (3, [M 29]), 183 (1, [M 3]);
182 (14, [M 2]), 181 (100, [M 1]), 180 (13, M), 179 (15, [M 1]), 165 (2), 153 (2), 137 (36), 126 (39),
125 (6), 112 (6), 109 (6), 99 (8), 91 (4), 87 (9), 73 (22), 55 (3), 45 (11), 41 (24). Anal. calc. for C11H16O2: C 73.30,
H 8.95; found: C 73.14, H 8.82.
(1R,4R,5R)-Spiro[bicyclo[2.2.1]heptane-2,2-[1,3]dioxolane]-5-ethanol (29). To a soln. of 28b (9.55 g,
53 mmol) in dry THF (100 ml), 0.5 9-BBN ¥THF complex soln. (233 ml, ca. 116.6 mmol) was added dropwise
at 0 under N2. After the addition was complete (3 h), the mixture was stirred for 5 h at r.t. and then cooled to 9
before 3 aq. NaOH (180 ml) was added. The thus obtained trialkylborane was oxidized by slow dropwise
addition of 30%H2O2 soln. (180 ml) at 0. After stirring overnight at r.t., the mixture was extracted with AcOEt
(4 200 ml), the combined extract washed with sat. Na2S2O3 soln. (3 80 ml) and brine (2 80 ml), dried
(Na2SO4), and evaporated, and the residue purified by CC (AcOEt/CH2Cl2 1 :2): 10.19 g (97%) of 29 (Rf 0.39).
Colorless oil. []23D 36.3 (c 0.54, CHCl3). 1H-NMR (500.13 MHz, CDCl3): 3.96 ± 3.82 (m, OCH2CH2O);
3.67 ± 3.63 (m, CH2CH2OH); 2.13 (m, HC(1)); 2.03 (m, HC(4)); 1.93 (ddd, J 12.64, 8.09, 2.11, 1 HC(6));
1.84 (dd, J 13.13, 4.80, 1 HC(3)); 1.65 ± 1.58 (m, 3 H); 1.55 (dm, J 10.11, 1 HC(7)); 1.47 ± 1.43 (m, 2 H);
1.41 (dm, J 10.19, 1 HC(7)); 0.97 (ddd, J 12.64, 4.38, 4.38, 1 HC(6)). 13C-NMR (50.3 MHz, CDCl3):
115.98 (C(2)); 64.48, 63.86 (OCH2CH2O); 61.64 (CH2CH2OH); 44.32 (C(3)); 44.17 (C(1)); 40.53 (C(4)); 39.73
(CH2CH2OH); 37.14 (C(5)); 34.78, 30.41 (C(6), C(7)). CI-MS (CH4): 239 (1, [M 41]), 227 (1, [M 29]), 200
(10, [M 2]), 199 (86, [M 1]), 198 (27, M), 197 (17, [M 1]), 183 (2), 182 (11), 181 (100), 167 (1), 153
(12), 137 (5), 126 (6), 119 (4), 99 (5), 87 (3), 73 (3). Anal. calc. for C11H18O3: C 66.64, H 9.15; found: C 66.62,
H 9.34.
(1R,4R,5R)-5-(2-Hydroxyethyl)bicyclo[2.2.1]heptan-2-one (30). As described for rac-syn-26a, with 29
(9.93 g, 50.1 mmol). Purification of the product (Rf 0.34) by CC (silica gel, AcOEt/CH2Cl2 1 :2) yielded 30 7.26 g
(94%). Colorless oil. []23D 53.2 (c 0.44, CHCl3). IR (CHCl3): 1740. 1H-NMR (500.13 MHz, CDCl3): 3.74 ±
3.65 (m, CH2CH2OH); 2.58 (m, HC(1)); 2.44 (m, HC(4)); 2.09 (dd, J 17.69, 4.70, 1 HC(3)); 1.85
(dd, J 17.69, 2.96, 1 HC(3)); 1.83 ± 1.71 (m, 4 H); 1.70 (m, 1 H); 1.66 (dm, J 10.61, 1 HC(7)); 1.56
(m, 1 H); 1.38 (dm, J 12.29, 2 HC(6)). 13C-NMR (50.3 MHz, CDCl3): 217.88 (C(2)); 61.34 (CH2CH2OH);
50.19 (C(1)); 45.61 (C(4)); 39.99 (C(3)); 39.38 (CH2CH2OH); 36.74 (C(5)); 34.72, 31.82 (C(6), C(7)). CI-MS
(CH4): 195 (4, [M 41]), 183 (9, [M 29]), 156 (16, [M 2]), 155 (100, [M 1]), 154 (10, M), 137 (25),
119 (12), 111 (13), 110 (14), 109 (27), 108 (9), 107 (7), 93 (39), 79 (6), 67 (8), 55 (3). Anal. calc. for C9H14O2:
C 70.10, H 9.15; found: C 69.96, H 9.40.
(1R,2S,4R)-Spiro[bicyclo[2.2.1]hept-5-ene-2,2-oxirane] (18). To a soln. of 17 [17] (185 g, 0.911 mol) in
MeOH (480 ml), K2CO3 (252 g, 1.822 mol) was added at r.t. After 10 h stirring, ice-cold H2O (960 ml) was
added, and the mixture was extracted with Et2O (4 200 ml). The combined extract was washed with brine (4
100 ml) and dried (MgSO4), the solvent distilled off through a short Vigreux column, and the residue purified by
CC (pentane/Et2O 6 :1): 102.4 g (92%) of 18 besides the 2-O-methyl ether corresponding to 19 (2.81 g, 2%).
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Data of 18 : Colorless oil. Rf 0.76. []20D 156 (c 1.16, CHCl3). 1H-NMR (500.13 MHz, CDCl3): 6.32
(dd, J 5.72, 2.92, HC(5)); 6.09 (dd, J 5.72, 3.20, HC(6)); 2.95 (m, HC(4)); 2.84 (d, J 4.57, 1 H,
CH2O); 2.81 (d, J 4.57, 1 H, CH2O); 2.32 (m, HC(1)); 1.92 (dm, J 8.51, 1 HC(7)); 1.77 (dm, J 8.51,
1 HC(7)); 1.69 (dd, J 12.53, 3.48, 1 HC(3)); 1.56 (dd, J 12.53, 2.83, 1 HC(3)). 13C-NMR (50.3 MHz,
CDCl3): 140.47 (C(5)); 133.12 (C(6)); 66.30 (C(2)); 50.97 (CH2O); 49.33 (C(7)); 48.91 (C(1)); 41.57 (C(4));
33.97 (C(3)). CI-MS (CH4): 151 (5, [M 29]), 137 (1, [M 15]), 124 (5, [M 2]), 123 (60, [M 1]), 122
(15,M), 121 (11, [M 1]), 113 (4), 105 (10), 95 (15), 91 (15), 85 (9), 81 (8), 80 (20), 79 (21), 67 (100), 66 (13),
57 (10).
Data of (1R,2S,4R)-2-Methoxybicyclo[2.2.1]hept-5-ene-2-methanol: Colorless oil. Rf 0.25. []22D 21.6
(c 3.25, CHCl3). 1H-NMR (200 MHz, CDCl3): 6.15 (dd, J 5.72, 2.92, HC(5)); 6.02 (dd, J 5.72, 3.20,
HC(6)); 3.38 (s, MeO); 3.27 (d, J 9.09, 1 H, CH2OH); 3.21 (d, J 9.09, 1 H, CH2OH); 2.83 (m, HC(4));
2.69 (m, HC(1)); 2.66 (s, OH); 1.92 (dm, J 8.50, 1 HC(7)); 1.62 (dd, J 12.31, 3.72, 1 HC(3)); 1.59
(dm, J 8.50, 1 HC(7)); 1.11 (dd, J 12.31, 2.73, 1 HC(3)). 13C-NMR (50.3 MHz, CDCl3): 138.98 (C(5));
134.10 (C(6)); 80.99 (C(2)); 78.66 (CH2OH); 59.19 (MeO); 51.25 (C(1)); 47.80 (C(7)); 41.25 (C(4)); 38.86
(C(3)). CI-MS (CH4): 155 (2, [M 1]), 154 (16,M), 138 (3, [(M 2) 18]), 137 (29, [(M 1) 18]), 136
(1, [M 18]), 123 (3), 122 (5), 121 (2), 109 (5), 105 (4), 95 (7), 89 (2), 88 (3), 87 (3), 81 (4), 72 (5), 71 (100),
66 (11).
(1R,2S,4R)-2-Hydroxybicyclo[2.2.1]hept-5-ene-2-methanol (19). To a stirred soln. of 18 (102 g, 0.835 mol)
in dioxane (700 ml), a soln. of KOH (281 g) in H2O (700 ml) was added, and stirring was continued for 48 h at
105. After cooling to r.t., the mixture was extracted by Et2O, washed with brine, dried (MgSO4), and
evaporated and the residue purified by CC (AcOEt/Et2O 1 :1): 114.7 g (98%) of 19 besides 1.6 g (1.5%) of the
corresponding [oxybis(methylene)]bis[bicyclo[2.2.1]heptene].
Data of 19. Rf 0.54. White solid. M.p. 82 ± 84 (hexane). []23D 26 (c 0.3, CHCl3). 1H-NMR (200 MHz,
CDCl3): 6.17 (dd, J 5.71, 2.92, HC(5)); 6.06 (dd, J 5.71, 3.13, HC(6)); 3.50 (d, J 11.00, 1 H, CH2OH);
3.42 (d, J 11.00, 1 H, CH2OH); 2.87 (m, HC(4)); 2.72 (m, HC(1)); 2.24 (br., 2 OH); 1.92 (dm, J 8.55,
1 HC(7)); 1.63 (dm, J 8.55, 1 HC(7)); 1.62 (dd, J 12.30, 3.72, 1 HC(3)); 1.18 (dd, J 12.30, 2.79,
1 HC(3)). 13C-NMR (50.3 MHz, CDCl3): 139.06 (C(5)); 133.79 (C(6)); 82.33 (C(2)); 68.60 (CH2OH); 50.59
(C(1)); 47.81 (C(7)); 41.37 (C(4)); 39.14 (C(3)). CI-MS (CH4): 141 (2, [M 1]), 140 (6,M), 123 (44), 113 (3),
109 (6), 105 (3), 95 (12), 85 (11), 81 (6), 79 (7), 67 (100), 66 (14), 57 (10). Anal. calc. for C8H12O2: C 68.55,
H 8.63; found: C 68.32, H 8.74.
Data of (1R,1R,4R,4R,5S,5S)-5,5-[Oxybis(methylene)]bis[bicyclo[2.2.1]hept-2-ene]: Rf 0.78. White
solid. M.p. 117 ± 118 (hexane). []20D 50.2 (c 0.54, CHCl3). 1H-NMR (200 MHz, CDCl3): 6.16 (dd, J
5.70, 2.94, HC(2), HC(2)); 6.01 (dd, J 5.70, 3.17, HC(3), HC(3)); 3.37 (d, J 9.33, 2 H, CH2OCH2);
3.19 (d, J 9.33, 2 H, CH2OCH2); 2.85 (m, HC(1), HC(1)); 2.71 (m, HC(4), HC(4)); 2.67 (br., 2 OH);
1.94 (dm, J 8.36, 2 H, HC(7), HC(7)); 1.66 (dm, J 8.55, 2 H, HC(7), HC(7)); 1.65 (dd, J 12.30,
3.71, 2 H, HC(6), HC(6)); 1.12 (dd, J 12.30, 2.66, 2 H, HC(6), HC(6)). 13C-NMR (50.3 MHz, CDCl3):
139.16 (2 C, C(2), C(2)); 133.96 (2 C, C(3), C(3)); 81.27 (2 C, C(5), C(5)); 77.43 (2 C, CH2OCH2); 51.31 (2 C,
C(4), C(4)); 47.78 (2 C, C(7), C(7)); 41.25 (2 C, C(1), C(1)); 38.82 (2 C, C(6), C(6)). CI-MS (CH4): 263 (2,
[M 1]), 246 (7, [(M 2) 18]), 245 (34, [(M 1) 18]), 244 (22, [M 18]), 227 (7), 180 (11), 179 (100),
178 (29), 177 (9), 161 (19), 133 (6), 124 (6), 123 (57), 122 (13), 113 (17), 105 (18), 95 (11), 79 (8), 67 (13). Anal.
calc. for C16H22O3: C 73.25, H 8.45; found: C 73.25, H 8.64.
(1R,4R,5S)-Spiro[bicyclo[2.2.1]heptane-2,2-[1,3]dioxolane]-5-methanol (31). Ozone was bubbled into a
soln. of 28b (9.91 g, 55 mmol) in CH2Cl2/MeOH 2 :1 (300 ml) at 78 until a blue color persisted. Thereafter,
the mixture was purged of ozone with N2 until the soln. became colorless, and NaBH4 (5.20 g, 137.5 mmol) was
added. The mixture was allowed to warm to r.t. and then stirred for 2 h before most of the solvent was
evaporated. Then, H2O (100 ml) was added, the aq. layer extracted with AcOEt (5 100 ml), the combined
extract washed with brine (2 50 ml), dried (Na2SO4), and evaporated, and the residue purified by CC (AcOEt/
CH2Cl2 1 :2): 9.71 g (96%) of 31. Rf 0.36. Colorless oil. []23D 17.2 (c 0.46, CHCl3). 1H-NMR (500.13 MHz,
CDCl3): 3.96 ± 3.81 (m, OCH2CH2O); 3.44 (dd, J 10.51, 6.23, 1 H, CH2OH); 3.40 (dd, J 10.51, 8.59, 1 H,
CH2OH); 2.24 (m, HC(1)); 2.13 (m, HC(4)); 1.89 (dd, J 13.30, 4.88, HC(3)); 1.86 (ddd, J 12.43, 8.44,
2.26, 1 HC(6)); 1.78 (m, HC(5)); 1.65 (br. s, CH2OH); 1.55 (dm, J 10.44, 1 HC(7)); 1.47 (dd, J 13.30,
3.53, 1 HC(3)); 1.36 (dm, J 10.44, 1 HC(7)); 0.91 (ddd, J 12.43, 4.55, 4.55, 1 HC(6)). 13C-NMR
(50.3 MHz, CDCl3): 116.05 (C(2)); 66.59 (CH2OH); 64.52, 63.88 (OCH2CH2O); 44.06 (C(3)); 43.77 (C(1));
43.55 (C(4)); 37.47 (C(5)); 34.56, 26.44 (C(6), C(7)). CI-MS (CH4): 186 (5, [M 2]), 185 (42, [M 1]), 184
(10,M), 183 (12, [M 1]), 168 (10), 167 (100), 153 (3), 141 (26), 123 (21), 113 (3), 105 (4), 99 (5), 95 (12), 79
(6), 73 (10), 67 (2), 55 (2). Anal. calc. for C10H16O3: C 65.19, H 8.75; found: C 65.10, H 8.92.
16
(1R,4R,5S)-5-(Hydroxymethyl)bicyclo[2.2.1]heptan-2-one (32). A soln. of 31 (9.55 g, 51.83 mmol) in
AcOH/H2O 3 :7 (100 ml) was stirred for 2 d at r.t. The mixture was then carefully neutralized by adding
dropwise 10% aq. NaOH soln. and then extracted with AcOEt (5 150 ml). The combined extract was washed
with brine (2 50 ml) and dried (Na2SO4) and the residue purified by FC (AcOEt/CH2Cl2 1 :1): 6.78 g (93%) of
32. Rf 0.33. Colorless oil. []23D 25.3 (c 0.85, CHCl3). IR (CHCl3): 1742. 1H-NMR (500.13 MHz, CDCl3):
3.56 (dd, J 10.61, 6.40, 1 H, CH2OH); 3.53 (dd, J 10.61, 8.59, 1 H, CH2OH); 2.65 (m, HC(1)); 2.59
(m, HC(4)); 2.14 (dd, J 17.69, 4.72, 1 HC(3)); 1.93 (m, HC(5)); 1.89 (dm, J 17.69, 1 HC(3)); 1.71
(dd, J 13.14, 8.59, 1 HC(6)); 1.69 ± 1.65 (m, 2 HC(7), CH2OH); 1.35 (ddd, J 13.14, 4.88, 4.88, 1 HC(6)).
13C-NMR (50.3 MHz, CDCl3): 217.60 (C(2)); 66.04 (CH2OH); 49.77 (C(1)); 45.46 (C(3)); 42.90 (C(4)); 37.16
(C(5)); 34.59, 28.08 (C(6), C(7)). CI-MS (CH4): 181 (2, [M 41]), 169 (5, [M 29]), 142 (8, [M 2]), 141
(100, [M 1]), 140 (8,M), 123 (26), 122 (4), 105 (5), 96 (3), 95 (24), 94 (3), 93 (6), 81 (7), 80 (3), 79 (15), 69
(1), 67 (4). Anal. calc. for C8H12O2: C 68.55, H 8.63; found: C 68.23, H 8.93.
(1R,5R,6S)-6-(Hydroxymethyl)-2-oxabicyclo[3.2.1]octan-3-one (33). As described for 14, procedure b),
with 32 (6.64 g, 47.4 mmol), NaHCO3 (7.97 g, 94.8 mmol), ca. 55% MCPBA (29.82 g, 94.8 mmol), and CH2Cl2
(650 ml): 6.29 g (85%) of 33.Rf 0.34. Colorless oil. []23D 13.7 (c 1.02, CHCl3). IR (CHCl3): 1726. 1H-NMR
(500.13 MHz, CDCl3): 4.87 (m, HC(1)); 3.55 (dd, J 10.52, 5.90, 1 H, CH2OH); 3.44 (dd, J 10.52, 8.16, 1 H,
CH2OH); 2.78 (dd, J 18.53, 4.96, 1 HC(4)); 2.56 (ddd, J 18.53, 2.27, 1.94, 1 HC(4)); 2.45 (m, HC(5));
2.35 (ddd, J 14.90, 8.72, 2.61, 1 HC(7)); 2.21 (m, HC(6)); 1.92 (dm, J 13.06, 1 HC(8)); 1.80 (dm, J
13.06, 1 HC(8)); 1.89 ± 1.72 (br., CH2OH); 1.53 (ddd, J 14.90, 5.31, 4.21, 1 HC(7)). 13C-NMR (50.3 MHz,
CDCl3): 170.29 (C(3)); 81.15 (C(1)); 65.60 (CH2OH); 44.90 (C(5)); 41.15 (C(4)); 36.27, 33.65 (C(7), C(8));
34.05 (C(6)). CI-MS (CH4): 158 (6, [M 2]), 157 (63, [M 1]), 140 (10), 139 (100), 121 (35), 111 (14), 97
(14), 95 (17), 94 (7), 93 (42), 81 (7), 79 (33), 67 (6), 61 (24). Anal. calc. for C8H12O3: C 61.52, H 7.74; found:
C 61.14, H 8.00.
Methyl (1R,2S,4R)-4-Hydroxy-2-(hydroxymethyl)cyclopentaneacetate (34a). As described for 15a, with 33
(5.3 g, 34 mmol): 34a (5.76 g, 90%). The crude product was used without further purification for the next step.
IR (CHCl3): 1726. 1H-NMR (500.13 MHz, CDCl3): 4.32 (m, HC(4)); 3.68 (s, MeO); 3.57 (d, J 5.81,
CH2OH); 2.64 (dd, J 16.15, 6.72, 1 H, CH2COO); 2.47 (dd, J 16.15, 6.71, 1 H, CH2COO); 2.56 ± 2.04
(m, 4 H); 1.83 (dddd, J 13.47, 7.59, 3.15, 1.66, 1 H); 1.62 (ddd, J 13.47, 9.08, 5.68, 1 H); 1.42 (dddd, J 13.36,
6.56, 4.01, 1.65, 1 H). 13C-NMR (50.3 MHz, CDCl3): 174.37 (CO); 72.49 (C(4)); 65.49 (CH2OH), 51.62 (MeO);
45.59 (C(2)); 41.80 (CH2CO2Me); 39.95, 39.14 (C(3), C(5)); 36.65 (C(1)). CI-MS (CH4): 217 (6, [M 29]), 190
(9, [M 2]), 189 (77, [M 1]), 172 (7), 171 (70), 154 (12), 153 (100), 139 (54), 121 (34), 111 (9), 93 (37), 79
(10), 75 (6), 61 (4).
Methyl (1R,2S,4R)-{{[(tert-Butyl)diphenylsilyl]oxy}methyl}-4-hydroxycyclopentaneacetate (34b). As de-
scribed for 15b, with 34a (5.84 g, 31 mmol): 34b (9.30 g, 70%). Colorless syrup. R (AcOEt/CH2Cl2 1 :8) 0.35.
[]23D 12.8 (c 0.75, CHCl3). IR (CHCl3): 1730. 1H-NMR (360 MHz, CDCl3): 7.68 ± 7.61 (m, 4 arom. H);
7.46 ± 7.34 (m, 6 arom. H); 4.31 (m, HC(4)); 3.63 (s, MeO); 3.60 (d, J 5.14, CH2O); 2.60 (dd, J 15.54, 4.42,
1 H, CH2COO); 2.38 (dd, J 15.54, 8.11, 1 H, CH2COO; 2.30 ± 2.08 (m, 3 H); 2.01 (br. s, OH); 1.83 ± 1.75
(m, 1 H); 1.72 ± 1.62 (m, 1 H); 1.44 ± 1.36 (m, 1 H); 1.05 (s, tBu). 13C-NMR (50.3 MHz, CDCl3): 176.68 (CO);
135.61, 133.76, 129.61, 127.64 (12 arom. C); 72.80 (C(4)); 66.35 (CH2O); 51.33 (MeO); 45.14 (C(2)); 41.87
(CH2CO2Me); 39.74, 39.10 (C(3), C(5)); 36.80 (C(1)); 26.88 (3 C, Me3C); 19.26 (Me3C). FAB-MS: 449 (13,
[MNa]), 427 (23, [M 1]), 409 (7), 369 (96), 343 (36), 331 (20), 239 (15), 213 (74), 199 (100), 183 (44),
153 (72), 135 (100), 121 (76). Anal. calc. for C25H34O4Si: C 70.38, H 8.03; found: C 69.98, H 8.06.
Methyl (1R,2S,4R)-{{[(tert-Butyl)diphenylsilyl]oxy}methyl}-4-[(methylsulfonyl)oxy]cyclopentaneacetate
(35). Methanesulfonyl chloride (1.77 g, 15.45 mmol) was added dropwise to a stirred, ice-cooled soln. of 34b
(5.07 g, 11.88 mmol) in CH2Cl2 (150 ml) containing DMAP (2.90 g, 23.76 mmol), and then the mixture was
stirred for 30 min before it was diluted with CH2Cl2 (150 ml). Then, the soln. was washed successively with sat.
aq. NaHCO3 soln. (80 ml) and brine (80 ml), dried (Na2SO4), and evaporated and the residue purified by CC
(AcOEt/petroleum ether 1 :2): 5.92 g (99%) of 35. Rf 0.79. Colorless syrup. []23D 16.2 (c 0.71, CHCl3). IR
(CHCl3): 1732. 1H-NMR (500.13 MHz, CDCl3): 7.66 ± 7.62 (m, 4 arom. H); 7.46 ± 7.36 (m, 6 arom. H); 5.13
(m, HC(4)); 3.63 (s, MeO); 3.64 (dd, J 10.28, 4.90, 1 H, CH2O); 3.59 (dd, J 10.28, 5.06, 1 H, CH2O); 2.99
(s, MeSO2); 2.60 ± 2.53 (m, 1 H); 2.43 (ddd, J 14.39, 8.15, 5.96, 1 H); 2.33 ± 2.22 (m, 2 H); 2.12 (dddd, J 13.48,
7.60, 2.84, 1.70, 1 H); 2.09 ± 2.02 (m, 1 H); 1.89 (ddd, J 13.28, 8.80, 5.76, 1 H); 1.72 (dddd, J 14.39, 6.93, 4.05,
1.60, 1 H); 1.05 (s, tBu). 13C-NMR (125.76 MHz, CDCl3): 172.96 (CO); 135.55, 133.30, 129.73, 127.72
(12 arom. C); 83.33 (C(4)); 65.13 (CH2O), 51.53 (MeO); 45.03 (MeSO2); 39.57, 39.52 (C(3), C(5)); 38.43,
36.14 (C(1), C(2)); 36.57 (CH2CO2Me); 26.83 (3 C,Me3C); 19.23 (Me3C). FAB-MS: 527 (5, [MNa]), 505 (4,
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[M 1]), 473 (6), 447 (51), 427 (13), 409 (25), 377 (6), 351 (21), 331 (37), 277 (73), 257 (18), 239 (24), 213
(100), 183 (82), 153 (100), 121 (100). Anal. calc. for C26H36O6SSi: C 61.87, H 7.19; found: C 61.83, H 7.02.
Methyl (1R,2S,4S)-4-(6-Amino-9H-purin-9-yl)-2-{{[(tert-butyl)diphenylsilyl]oxy}methyl}cyclopentaneace-
tate (36). Adenine (1.21 g, 8.93 mmol) and K2CO3 (1.65 g, 11.90 mmol) were added to a soln. of 35 (3.0 g,
5.95 mmol) in dry DMSO (30 ml), and the mixture was stirred at 85 for 1 d. After evaporation, the residue was
dissolved in CH2Cl2 (1.2 l), the soln. washed successively with H2O (3 100 ml) and brine (3 100 ml), dried
(Na2SO4), and evaporated, and the residue purified by CC (CH2Cl2/EtOH 20 :1): 1.86 g (58%) of 36. Rf 0.22.
White solid. M.p. 134 ± 135 (from CH2Cl2/petroleum ether). []24D 11.43 (c 0.84, CHCl3). UV (CHCl3): 262
(21600). IR (KBr): 1740, 1667, 1599. 1H-NMR (500.13 MHz, CDCl3): 8.35 (s, HC(2)); 7.88 (s, HC(8));
7.68 ± 7.62 (m, 4 arom. H); 7.46 ± 7.36 (m, 6 arom. H); 5.99 (s, NH2); 4.99 (m, 1 HC(4)); 3.76 (dd, J 10.33,
4.67, 1 H, CH2O); 3.71 (dd, J 10.33, 5.07, 1 H, CH2O); 3.64 (s, MeO); 2.65 ± 2.54 (m, 2 H); 2.51 ± 2.45 (m, 1 H);
2.39 ± 2.26 (m, 2 H); 2.10 (m, 1 H); 2.04 ± 1.94 (m, 2 H); 1.07 (s, tBu). 13C-NMR (50.3 MHz, CDCl3): 172.80
(CO); 155.48 (C(6)); 152.70 (C(2)); 150.07 (C(4)); 138.42 (C(8)); 135.56, 133.31, 129.76, 127.72 (12 arom. C);
119.95 (C(5)); 65.21 (CH2O); 53.62 (C(4)); 51.59 (MeO); 46.29 (C(1)); 39.11, 38.47 (C(3), C(5)); 36.42
(CH2CO2Me); 36.09 (C(2)); 26.88 (3 C,Me3C); 19.25 (Me3C). FAB-MS: 546 (13, [M 2]), 545 (34, [M 1]),
544 (79,M), 486 (10), 466 (9), 288 (40), 255 (8), 213 (44), 197 (44), 183 (31), 136 (100), 121 (50). Anal. calc.
for C30H37N5O3Si: C 66.27, H 6.86, N 12.88; found: C 66.17, H 7.00, N 12.85.
Methyl (1R,2S,4S)-2-{{[(tert-Butyl)diphenylsilyl]oxy}methyl}-4-(1,2,3,4-tetrahydro-5-methyl-2,4-dioxopy-
rimidin-1-yl)cyclopentaneacetate (37). A mixture of 35 (1.45 g, 2.87 mmol) and thymine (906 mg, 7.18 mmol)
in dry DMF (20 ml) containing [18]crown-6 (1.14 g, 4.31 mmol) as phase-transfer catalyst, and K2CO3 (992 mg,
7.18 mmol) was stirred at 85 for 2 d. After dilution with AcOEt (1 l), the mixture was washed successively with
H2O (4 100 ml) and brine (100 ml), dried (Na2SO4), and evaporated and the residue purified by FC (AcOEt/
CH2Cl2/EtOH 20 :40 :1): 599 mg (39%) of 37. Rf 0.58. White frothy solid. M.p. 48 ± 51. []24D 2.27 (c 0.22,
CHCl3). UV (CHCl3): 272 (13100). IR (KBr): 1736, 1690. 1H-NMR (500.13 MHz, CDCl3): 8.98 (s, HN(3));
7.67 ± 7.62 (m, 4 arom. H); 7.47 ± 7.36 (m, 6 arom. H); 7.04 (d, J 1.12, HC(6)); 5.05 (m, 1 HC(4)); 3.72
(dd, J 10.44, 4.58, 1 H, CH2O); 3.69 (dd, J 10.44, 4.90, 1 H, CH2O); 3.64 (s, MeO); 2.51 (dd, J 15.45, 4.58,
1 H); 2.48 ± 2.41 (m, 1 H); 2.25 ± 2.20 (m, 1 H); 2.19 (dd, J 15.45, 9.16, 1 H); 2.04 ± 2.18 (m, 1 H); 1.91 (d, J
1.12, MeC(5)); 1.90 ± 1.80 (m, 2 H); 1.63 (m, 1 H); 1.07 (s, tBu). 13C-NMR (125.76 MHz, CDCl3): 172.84
(CO); 163.56 (C(4)); 151.08 (C(2)); 136.29 (C(6)); 135.53, 133.26, 129.79, 127.73 (12 arom. C); 111.27 (C(5));
64.65 (CH2O); 53.62 (C(4)); 51.56 (MeO); 45.91 (C(1)); 38.92, 37.00, 36.13 (C(2)); 35.18, 26.88 (3 C, Me3C);
19.24 (MeC(5)); 12.62 (Me3C). FAB-MS: 559 (3, [(M 1)Na]), 558 (11, [MNa]), 557 (27, [(M 1)
Na]), 536 (10, [M 1]), 535 (26, M), 477 (35), 457 (16), 409 (5), 369 (4), 351 (15), 331 (14), 307 (20), 287
(10), 279 (34), 247 (18), 213 (85), 197 (10), 183 (53), 153 (66), 135 (100). HR-ESI-MS (MeOH/CHCl3):
557.2432 (C30H38N2O5SiNa, [MNa] ; calc. 557.2442). Anal. calc. for C30H38N2O5Si: C 67.39, H 7.16, N 5.24;
found: C 66.90, H 7.38, N 4.98.
Ethyl (1R,2R,3R,4S,5R)-7-Oxo-6-oxatricyclo[3.3.1.02,4]nonane-3-carboxylate (syn-38). As described for 14,
procedure b), with syn-11 (4.94 g, 25.43 mmol), NaHCO3 (4.27 g, 50.86 mmol), CH2Cl2, and MCPBA (15.96 g,
50.86 mmol) (20 h). Purification by CC (AcOEt/petroleum ether 1 : 1) yielded 5.19 g (97%) of syn-38. Colorless
solid. M.p. 85 ± 87. []22D 67.1 (c 0.83, CHCl3). IR (KBr): 1726. 1H-NMR (360 MHz, CDCl3): 4.87
(m, HC(5)); 4.14 (dq, J 7.13, 2.18, MeCH2O); 2.79 (dd, J 18.34, 4.66, HC(8)); 2.71 ± 2.64 (m, 1 HC(8),
HC(1)); 2.16 (ddm, J 7.13, 6.94, HC(3)); 1.88 (dd, J 8.32, 8.12, HC(4)); 1.76 (dm, J 14.66,
1 HC(9)) ; 1.74 (m, HC(2)); 1.43 (dm, J 14.66, 1 HC(9)) ; 1.26 (t, J 7.1, MeCH2O). 13C-NMR
(50.3 MHz, CDCl3): 169.96 (CO); 169.71 (CO); 79.40 (C(5)); 61.47 (MeCH2O); 41.19 (C(8)); 31.51 (C(1));
30.34 (C(9)); 26.48 (C(4)); 25.61 (C(3)); 24.95 (C(2)); 14.00 (MeCH2O). CI-MS (CH4): 239 (2, [M 29]), 212
(13, [M 2]), 211 (100, [M 1]), 193 (24), 183 (6), 166 (8), 165 (60), 151 (3), 138 (7), 137 (44). 119 (10), 93
(10), 91 (14), 79 (2), 57 (4), 43 (4). Anal. calc. for C11H14O4: C 62.85, H 6.71; found: C 62.85, H 6.96.
Ethyl (1R,2R,3S,4S,5R)-7-Oxo-6-oxatricyclo[3.3.1.02,4]nonane-3-carboxylate (anti-38). As described for 33,
with anti-11 (8.71 g, 44.84 mmol), NaHCO3 (7.53 g, 89.69 mmol), CH2Cl2, and MCPBA (28.14 g, 89.69 mmol)
(20 h). Purification as described for syn-38 yielded 8.40 g (89%) of anti-38. White solid. M.p. 124 ± 125. []22D 
23.2 (c 0.93, CHCl3). IR (KBr): 1723. 1H-NMR (500.13 MHz, CDCl3): 4.81 (m, HC(5)); 4.13 (q, J 7.13,
MeCH2O); 2.78 (dd, J 18.36, 4.41, 1 HC(8)); 2.71 (ddd, J 18.36, 1.97, 1.97, 1 HC(8)); 2.57 (m, HC(1));
2.36 (dm, J 6.36, HC(4)); 1.99 (ddm, J 6.30, 2.99, HC(2)); 1.72 (dm, J 14.07, 1 HC(9)); 1.68 (dd, J
2.73, 2.73, HC(3)); 1.46 (dm, J 14.07 Hz, 1 HC(9)); 1.26 (t, J 7.13, MeCH2O). 13C-NMR (50.3 MHz,
CDCl3): 171.08 (CO); 169.37 (C(7)); 78.86 (C(5)); 60.94 (MeCH2O); 40.35 (C(8)); 31.69 (C(1)); 29.54 (C(4));
29.43 (C(9)); 28.59 (C(3)); 22.15 (C(2)); 14.11 (MeCH2O). CI-MS (CH4): 251 (1, [M 41]), 239 (4, [M
18
29]), 212 (13, [M 2]), 211 (100, [M 1]), 210 (8, M), 193 (30), 183 (5), 166 (8), 165 (69), 137 (23), 119
(5), 107 (2), 93 (5), 91 (7), 41 (4). Anal. calc. for C11H14O4: C 62.85, H 6.71; found: C 62.88, H 6.83.
Ethyl 3-Oxo-2-oxabicyclo[3.2.1]octane-7-exo-acetate (rac-39). A soln. of rac-syn-38 (52 mg, 24.7 mmol) in
MeOH (20 ml) was hydrogenated for 15 h at r.t./1 atm over 10% Pd/C (112 mg). The catalyst was filtered off,
the filtrate evaporated, and the residue purified by CC (AcOEt/petroleum ether 1 :1): 13 mg (25%) of rac-39.
Colorless oil. 1H-NMR (360 MHz, CDCl3): 4.59 (m, HC(5)) ; 4.15 (q, J 7.13, MeCH2O); 2.85
(m, 1 HC(6)); 2.75 (ddd, J 18.54, 5.13, 2.57, HC(2)); 2.57 (m, HC(1)); 2.51 (dm, J 18.54, HC(2));
2.36 (dd, J 15.26, 7.6, 1 HC(6)); 2.20 (dd, J 15.26, 8.42, 1 HC(6)); 2.09 (ddd, J 13.69, 8.56, 2.28,
1 HC(7)); 1.96 (dm, J 13.69, 1 HC(7)); 1.76 (dm, J 13.12, 1 HC(8)); 1.49 (dm, J 13.12, 1 HC(8));
1.27 (t, J 7.13, MeCH2O). NOE: 2.85 (2.8, 4.59), 2.36 (2.9, 4.59), 1.76 (1.6, 4.59), 4.59 (2.3, 2.85), 2.36 (1.7,
2.85), 2.20 (1.63, 2.85), 2.75 (4.2, 2.57), 1.76 (1.9, 2.57), 1.49 (20, 2.57). 13C-NMR (50.3 MHz, CDCl3): 169.94
(CO); 83.81 (C(5)); 60.73 (CH2O); 41.76 (C(6)); 40.24 (C(2)); 39.44 (CH2COO); 37.29, 33.50 (C(7), C(8));
32.41 (C(1)); 14.63 (MeCH2O). CI-MS (CH4): 212 (6, [M 2]), 213 (45, [M 1]), 196 (12), 195 (100), 184
(3), 167 (47), 154 (5), 153 (65), 139 (6), 121 (3), 93 (3), 41 (23).
Methyl (1R,2R,4R,5S,6S)-4-Hydroxy-6-(methoxycarbonyl)bicyclo[3.1.0]hexane-2-acetate (anti-40). A soln.
of anti-38 (8.30 g, 39.48 mmol) in MeOH (180 ml) containing 37% aq. HCl soln. (9.87 ml, 118.44 mmol) was
refluxed for 48 h and then cooled and evaporated. The residual liquid was partitioned between AcOEt (100 ml)
and H2O (100 ml), the aq. layer extracted with AcOEt (4 100 ml), the combined org. extract washed with H2O
(100 ml) and brine (100 ml), dried (Na2SO4), and evaporated: 8.74 g (97%) of anti-40 as a slightly yellow oil
which was transformed into anti-41 without further purification. IR (CDCl3): 1724. 1H-NMR (360 MHz,
CDCl3): 4.35 (d, J 5.25, 1 HC(4)); 3.69 (s, MeO); 3.66 (s, MeO); 2.69 ± 2.53 (m, 3 H); 2.07 (m, 1 H); 1.97
(dd, J 5.81, 3.00, 1 H); 1.64 (ddd, J 15.32, 6.93, 5.43, 1 H); 1.50 (dm, J 15.32, 1 H); 1.29 (dd, J 3.18, 3.00,
1 H). 13C-NMR (50.3 MHz, CDCl3): 173.27 (CO); 172.97 (CO); 73.72 (C(4)); 51.76 (MeO); 51.56 (MeO); 40.39
(CH2CO2Me); 37.11 (C(3)); 36.09; 34.48; 32.45; 22.22. CI-MS (CH4): 269 (1, [M 41]), 258 (2, [(M 29)
1]), 257 (19, [M 29]), 229 (11, [M 1]), 228 (5,M), 212 (15), 211 (100), 197 (12), 180 (5), 179 (51), 152
(3), 151 (43), 137 (3), 119 (7), 91 (9).
rac-Methyl 6-(Methoxycarbonyl)-4-oxobicyclo[3.1.0]hexane-2-acetate (syn-41). As described for anti-40,
with rac-syn-38 (2.10 g, 10 mmol), MeOH (45 ml), and containing 37% aq. HCl soln. (2.5 ml, 30 mmol). The
product, rac-syn-40, was added, without further purification, into a stirred suspension of PCC (3.14 g,
14.55 mmol) in CH2Cl2 (100 ml). After 2 h, dry Et2O (100 ml) was added, and the supernatant liquid was
decanted from a black gummy residue, which was washed with dry Et2O (3 200 ml) until it became a black
granular solid. The combined org. soln. was filtered through a short pad of Florisil, the filtrate evaporated, and
the residue purified by CC (AcOEt/petroleum ether 1 : 2): 678.7 mg (30%) of rac-syn-41. Colorless oil. 1H-NMR
(200 MHz, CDCl3): 3.717 (s, MeO); 3.707 (s, MeO); 2.86 ± 2.67 (m, 2 H); 2.63 ± 2.56 (m, 2 H); 2.35 ± 2.24
(m, 3 H); 2.10 ± 1.91 (m, 1 H). 13C-NMR (50.3 MHz, CDCl3): 210.80 (C(4)); 171.74 (CO); 169.77 (CO); 52.08
(MeO); 51.52 (MeO); 44.68 (C(3)); 40.40 (CH2COO); 34.34; 34.12; 30.12; 27.94. CI-MS (CH4): 267 (3, [M
41]), 255 (5, [M 29]), 228 (7, [M 2]), 227 (56, [M 1]), 196 (12), 195 (100), 167 (10), 153 (5), 135 (5),
121 (3), 107 (4), 98 (3).
Methyl (1R,2R,5S,6S)-6-(Methoxycarbonyl)-4-oxobicyclo[3.1.0]hexane-2-acetate (anti-41). Crude anti-40
(8.74 g, 38.30 mmol) was added in one portion to a stirred suspension of PCC (12.38 g, 57.45 mmol) in anh.
CH2Cl2 (400 ml). After 2 h, the product (Rf 0.33) was isolated and purified as described for syn-41: 5.29 g (61%)
of anti-41. White solid. M.p. 100.5 ± 101.5. []23D 2.04 (c 1.03, CHCl3). IR (KBr): 1726. 1H-NMR
(360 MHz, CDCl3): 3.71 (s, MeO); 3.70 (s, MeO); 2.86 (m, HC(2)); 2.54 (dd, J 16.26, 7.41, 1 H, CH2COO);
2.45 (dd, J 16.26, 7.13, 1 H, CH2COO); 2.43 (dd, J 5.56, 3.57, HC(5)); 2.32 (m, HC(1)); 2.31 (dd, J
19.11, 8.85, 1 HC(3)); 2.08 (m, HC(6)); 1.88 (dm, J 19.11, 1 HC(3)). NOE: 2.54 (2.07, 2.86), 2.45 (6.22,
2.86), 2.31 (4.77, 2.86), 2.08 (4.51, 2.86), 2.86 (4.33, 2.08). 13C-NMR (50.3 MHz, CDCl3): 209.46 (C(4)); 171.56
(CO); 170.33 (CO); 52.26 (MeO); 51.70 (MeO); 39.73 (CH2CO2Me); 38.58 (C(3)); 35.00; 33.66; 31.90; 26.31.
CI-MS (CH4): 267 (2, [M 41]), 255 (5, [M 29]), 228 (5, [M 2]), 227 (49, [M 1]), 196 (10), 195 (100),
181 (4), 167 (10), 153 (8), 135 (7), 107 (8), 98 (18), 79 (1), 45 (5). Anal. calc. for C11H14O5: C 58.40, H 6.24;
found: C 58.47, H 6.25.
Dimethyl (1R,2R)-4-Oxocyclopentane-1,2-diacetate (42). A soln. of anti-41 (3.51 g, 15.50 mmol) in MeOH
(160 ml) was hydrogenated for 15 h at r.t./1 atm over 10% Pd/C (1.05 g). The catalyst was filtered off, the filtrate
evaporated, and the residue purified by FC (AcOEt/petroleum ether 1 :3): 3.22 g (91%) of 42. Colorless oil.
Rf 0.32. []23D 136.2 (c 0.52, CHCl3). IR (CHCl3): 1740, 1728. 1H-NMR (360 MHz, CDCl3): 3.69
(s, 2 MeO); 2.70 ± 2.56 (m, CH2(3), CH2(5)); 2.39 ± 2.28 (m, 2 CH2COO); 2.06 ± 1.96 (m, HC(1), HC(2)).
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13C-NMR (50.3 MHz, CDCl3): 215.31 (C(4)); 172.12 (2 C, 2 CO); 51.58 (2 C, 2 MeO); 44.48 (2 C, C(3), C(5));
38.19 (2 C, C(1), C(2)); 37.53 (2 C, 2 CH2COO). CI-MS (CH4): 269 (1, [M 41]), 257 (2, [M 29]), 229 (33,
[M 1]), 198 (11), 197 (100, [MMeO]), 183 (11), 169 (6), 168 (4), 155 (12). Anal. calc. for C11H16O5:
C 57.89, H 7.07; found: C 57.73, H 7.09.
Dimethyl (1R,2R)-4-Hydroxycyclopentane-1,2-diacetate (43). NaBH4 (481 mg, 12.71 mmol) was added in
one portion into a stirred soln. of 42 (2.90 g, 12.71 mmol) in MeOH (40 ml) at 0. After 1 h stirring at 0, most of
the solvent was evaporated before H2O (40 ml) was added. The mixture was extracted with AcOEt (5 40 ml),
the combined extract washed with brine (50 ml), dried (Na2SO4), and evaporated, and the residue purified by
CC (AcOEt/petroleum ether 1 : 1): 2.69 g (92%) of 43. Colorless oil. Rf 0.36. []23D 39.1 (c 0.47, CHCl3). IR
(CHCl3): 1728. 1H-NMR (360 MHz, CDCl3): 4.33 (m, HC(4)); 3.674 (s, MeO); 3.671 (s, MeO); 2.58 (dd, J
15.76, 5.05, 1 H); 2.51 (dd, J 14.27, 4.56, 1 H); 2.38 (dd, J 15.76, 8.62, 1 H); 2.23 (dd, J 14.27, 8.72, 1 H);
2.33 ± 2.25 (m, 2 H); 2.00 ± 1.92 (m, 2 H); 1.76 (br. s, OH); 1.53 (ddd, J 13.72, 9.91, 5.75, 1 H); 1.40 (dddd, J
13.72, 7.53, 3.57, 1.58, 1 H). 13C-NMR (50.3 MHz, CDCl3): 173.43 (CO); 173.11 (CO); 71.99 (C(4)); 51.45
(2 MeO); 42.33, 41.64 (C(3), C(5)); 40.11, 39.39 (C(1), C(2)); 39.01, 38.62 (2 CH2COO). CI-MS (CH4): 259 (6,
[M 29]), 231 (18, [M 1]), 214 (6), 213 (50), 199 (3), 182 (11), 181 (100), 167 (3), 153 (15), 152 (2), 139
(12). Anal. calc. for C11H18O5: C 57.38, H 7.88; found: C 57.21, H 7.94.
Methyl (1R,2S,4S)-2-{2-{[(tert-Butyl)diphenylsilyl]oxy}ethyl}-4-[(methylsulfonyl)oxy]cyclopentaneacetate
(44). To a stirred soln. of 15b (925 mg, 2.10 mmol) in CH2Cl2 (35 ml), Et3N (533 mg, 5.26 mmol) and
methanesulfonyl chloride (602 mg, 5.26 mmol) were successively added, and the mixture was stirred for 2 d at
r.t. The residue obtained after evaporation was purified by CC (AcOEt/petroleum ether 1 : 2): 1.035 g (95%) of
44. Colorless syrup. Rf 0.49. []23D 29.8 (c 0.47, CHCl3). IR (CHCl3): 1732. 1H-NMR (500.13 MHz, CDCl3):
7.67 ± 7.63 (m, 4 arom. H); 7.45 ± 7.36 (m, 6 arom. H); 5.10 (m, HC(4)); 3.73 ± 3.61 (m, CH2CH2O); 3.66
(s, MeO); 2.95 (s, MeSO2); 2.57 (dd, J 15.56, 3.94, 1 H); 2.44 (ddd, J 14.65, 7.84, 6.50, 1 H); 2.25 (dd, J
15.56, 9.48, 1 H); 2.17 (m, 1 H); 1.97 ± 1.87 (m, 2 H); 1.81 (m, 1 H); 1.67 (m, 1 H); 1.51 (ddd, J 14.40, 10.06,
6.08, 1 H); 1.37 (m, 1 H); 1.05 (s, tBu). 13C-NMR (125.76 MHz, CDCl3): 173.11 (CO); 135.51, 133.65, 129.66,
127.68 (12 arom. C); 83.00 (C(4)); 62.52 (CH2CH2O); 51.60 (MeO); 40.29 (MeSO2); 39.95 (C(1) or C(2)); 39.83,
39.31 (C(3), C(5)); 38.88 (CH2CH2O); 38.42 (C(2) or C(1)); 36.51 (CH2CO2Me); 26.82 (3 C, Me3C); 19.13
(Me3C). FAB-MS: 542 (2, [MNa]), 520 (4, [M 1]), 488 (6), 461 (37), 441 (13), 421 (7), 391 (6), 365 (33),
345 (56), 277 (56), 257 (18), 239 (26), 213 (100), 183 (100), 137 (100). Anal. calc. for C27H38OSSi: C 62.52,
H 7.38; found: C 62.37, H 7.49.
Methyl (1R,2R,4R)-4-(6-Amino-9H-purin-9-yl)-2-{2-{[(tert-butyl)diphenylsilyl]oxy}ethyl}cyclopentane-
acetate (45). As described for 36, with 44 (220 mg, 424 mmol): 45 (135 mg, 57%). White solid. M.p. 126 ±
126.5 (from CH2Cl2/petroleum ether). Rf (CH2Cl2/EtOH 20 :1) 0.20. []24D 23.86 (c 0.44, CHCl3). IR
(KBr): 1738, 1669, 1643, 1601. UV (CHCl3): 262 (15600). 1H-NMR (500.13 MHz, CDCl3): 8.35 (s, HC(2));
7.84 (s, HC(8)); 7.67 ± 7.63 (m, 4 arom. H); 7.44 ± 7.35 (m, 6 arom. H); 5.86 (s, NH2); 4.90 (m, HC(4)); 3.77 ±
3.62 (m, CH2CH2O); 3.67 (s, MeO); 2.60 (dd, J 15.10, 3.48, 1 H); 2.42 (m, 1 H); 2.37 ± 2.24 (m, 3 H); 2.13 ±
2.05 (m, 1 H); 1.94 ± 1.80 (m, 2 H); 1.68 (m, 1 H); 1.52 (m, 1 H); 1.05 (s, tBu). 13C-NMR (50.3 MHz, CDCl3):
172.98 (CO); 155.18 (C(6)); 152.29 (C(2)); 150.01 (C(4)); 138.64 (C(8)); 135.50, 133.64, 129.67, 127.67
(12 arom. C); 119.95 (C(5)); 62.40 (OCH2CH2); 53.78 (C(4)); 51.63 (MeO); 41.11, 40.02 (C(1), C(2)); 39.52,
38.71, 38.07, 36.74, 26.87 (3 C,Me3C); 19.16 (Me3C). FAB-MS: 560 (11, [M 2]), 559 (38, [M 1]), 558 (87,
M), 500 (23), 480 (5), 302 (10), 213 (27), 197 (34), 183 (23), 136 (100), 121 (34). Anal. calc. for C31H39N5O3Si:
C 66.76, H 7.05, N 12.56; found: C 66.56, H 6.97, N 12.39.
Methyl (1R,2R,4R)-2-{2-{[(tert-Butyl)diphenylsilyl]oxy}ethyl}-4-(1,2,3,4-tetrahydro-5-methyl-2,4-dioxo-
pyrimidin-1-yl)cyclopentaneacetate (46). As described for 37, with 44 (210 mg, 405 mmol): 46 (77.8 mg, 35%).
White foamy solid. M.p. 43 ± 45. Rf (AcOEt/CH2Cl2/EtOH 20 :40 :1) 0.62. []24D 15.91 (c 0.22, CHCl3).
UV (CHCl3): 272 (13400). IR (KBr): 1738, 1688. 1H-NMR (500.13 MHz, CDCl3): 8.81 (s, HC(3)); 7.66 ± 7.62
(m, 4 arom. H); 7.45 ± 7.36 (m, 6 arom. H); 7.00 (d, J 1.17, HC(6)) ; 4.92 (m, HC(4)); 3.75 ± 3.60
(m, CH2CH2O); 3.67 (s, MeO); 2.56 (dd, J 15.02, 3.30, 1 H); 2.19 (dd, J 15.02, 9.90, 1 H); 2.18 ± 2.10
(m, 2 H); 2.01 ± 1.94 (m, 1 H); 1.93 (d, J 1.17, MeC(5)); 1.91 ± 1.82 (m, 2 H); 1.75 ± 1.65 (m, 1 H); 1.43
(m, 1 H); 1.26 (m, 1 H); 1.05 (s, tBu). 13C-NMR (125.76 MHz, CDCl3): 173.07 (CO); 163.54 (C(4)); 150.93
(C(2)); 136.52 (C(6)); 135.51, 133.64, 129.68, 127.68 (12 arom. C); 111.12 (C(5)); 62.33 (CH2O); 54.03 (C(4));
51.61 (MeO); 40.79, 40.30 (C(1), C(2)); 38.58, 38.46, 36.49, 36.43, 26.85 (3 C, Me3C); 19.13 (MeC(5)); 12.60
(Me3C). FAB-MS: 550 (3, [M 1]), 549 (8,M), 491 (23), 471 (23), 365 (6), 345 (11), 307 (15), 287 (10), 247
(11), 213 (34) , 197 (52), 167 (29) , 135 (100) , 127 (68). HR-ESI-MS (MeOH/CHCl3): 571.2596
(C31H40N2O5SiNa, [MNa] ; calc. 571.2599). Anal. calc. for C31H40N2O5Si: C 67.85, H 7.35, N 5.10; found:
C 67.47, H 7.59, N 4.80.
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